University of New Mexico

UNM Digital Repository
Biomedical Sciences ETDs

Electronic Theses and Dissertations

7-1-2011

Small molecule inhibition of Staphylococcus
aureus virulence
Erin Sully

Follow this and additional works at: https://digitalrepository.unm.edu/biom_etds
Recommended Citation
Sully, Erin. "Small molecule inhibition of Staphylococcus aureus virulence." (2011). https://digitalrepository.unm.edu/biom_etds/39

This Dissertation is brought to you for free and open access by the Electronic Theses and Dissertations at UNM Digital Repository. It has been
accepted for inclusion in Biomedical Sciences ETDs by an authorized administrator of UNM Digital Repository. For more information, please contact
disc@unm.edu.

Erin Sully
Candidate

Department of Internal Medicine
Department

This dissertation is approved, and it is acceptable in quality
and form for publication:
Approved by the Dissertation Committee:

ii

SMALL MOLECULE INHIBITION OF
STAPHYLOCOCCUS AUREUS VIRULENCE

BY

ERIN SULLY
B.S., Biomedical Sciences, University of California, Irvine, 2003

DISSERTATION
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Doctor of Philosophy
Biomedical Sciences
The University of New Mexico
Albuquerque, New Mexico

July, 2011

iii

ACKNOWLEDGMENTS

My deepest thanks to my advisor and committee chair Dr. Hattie Gresham and my
committee member Dr. Pam Hall for their support and guidance during my doctoral education. I
also thank my committee members, Dr. Carolyn Mold and Dr. Michelle Ozbun, for their advice
and their contributions of time and knowledge to my project.
Thank you to the members of the laboratory who have been invaluable for their support
and assistance: Susan Alexander, Martha Terrazas, Cynthia Spang, and Stephany Delgado, as
well as former members of the lab who laid the foundation for the work presented in this
manuscript: Anny Alsup, Dr. Youhanna Sawires, Dr. Michel Peterson, and Dr. Jacob Rothfork.
Finally, I thank my family and friends who have given me the encouragement and
support to persevere and achieve my goals. I thank you all.

iv

SMALL MOLECULE INHIBITION OF
STAPHYLOCOCCUS AUREUS VIRULENCE

BY

ERIN SULLY

ABSTRACT OF DISSERTATION
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Doctor of Philosophy
Biomedical Sciences
The University of New Mexico
Albuquerque, New Mexico

July, 2011

v
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by
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Ph.D., Biomedical Sciences, University of New Mexico, 2011

ABSTRACT
The increasing emergence of antibiotic resistant Staphylococcus aureus infections, particularly
those caused by a single clone of methicillin resistant S. aureus (USA300 MRSA), coupled with
the slowing of antibiotic discovery makes research into novel therapies a priority (Lowy, 2007).
One strategy evolving is the development of drugs that target bacterial virulence factors as
opposed to growth (Cegelski et al., 2008). Due to the lack of selective pressure, bacterial
resistance to the drugs would be minimized while the infection, attenuated by the inhibition of
virulence factor production, could be cleared by the innate immune factors of the host. Virulence
factors identified to date as essential for invasive USA 300 MRSA infection are globally
regulated in part by a quorum sensing operon, agr (George and Muir, 2007; Novick and
Geisinger, 2008; Yarwood and Schlievert, 2003). Host factors like apolipoprotein B provide
defense by antagonizing agr signaling which demonstrates that host defense against an invasive
infection could be accomplished by blocking agr signaling (Peterson et al., 2008). Therefore, we
hypothesized that screening small molecule inhibitors for inhibition of agr signaling could
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contribute to drug discovery by providing optimal host defense against quorum sensing
dependent S. aureus infections. Our work focuses on two small molecule inhibitors, CID# 2333
and CID# 3243271, identified in a screen of over 20,000 compounds for antagonism of agr
signaling. These compounds demonstrate virulence factor inhibition in vitro and in an in vivo
model of community associated -MRSA dermonecrotic infection.
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CHAPTER 1
INTRODUCTION
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The Medical Impact of Staphylococcus aureus infection
Staphylococcus aureus, a common colonizer of the human skin and mucosa, can
cause illnesses ranging from minor skin infections and abscesses to life-threatening
diseases such as necrotizing pneumonia, endocarditis, and septicemia (Lowy, 1998). The
emergence of antibiotic resistant strains has become a healthcare and economic burden
associated with a 1.2-2.0-fold increase in length of hospital stay and an increase in
hospitalization costs ranging from $5000-$40,000 (Lodise and McKinnon, 2007; Naber,
2009). Given the burden of the disease and the absence of an effective vaccine, efforts
have been refocused to discover and develop drugs that can be effective therapeutics
against this infection.

Antibiotic Resistant S. aureus Infection
Methicillin-resistant S. aureus (MRSA) was first reported in 1961, 2 years after
methicillin was introduced to treat penicillin-resistant bacteria (Deleo et al., 2010). The
first reports of community-associated MRSA (CA-MRSA) came in 1993 from Western
Australia (Udo et al., 1993). These strains were isolated from otherwise healthy people
who had no predisposing risk factors for MRSA infection such as wounds, indwelling
medical devices, or extended hospital stays. These strains were more virulent than the
hospital-associated MRSA (HA-MRSA) due to the presence of various virulence factors
that cause aggressive invasive disease (Chambers, 2001). Recently CA-MRSA has been
replacing HA-MRSA in healthcare facilities, especially in the United States (Klevens et
al., 2006).
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In addition to being isolated from people lacking the predisposing risk factors
described above, CA-MRSA can also be defined based on genetic markers. Unlike HAMRSA strains which usually contain type I, II, or III staphylococcal cassette chromosome
mec (SCCmec), CA-MRSA isolates contain type IV SCC(Chambers, 2005)mec
(Chambers, 2005). SCCmecIV contains the mecA gene which encodes for specific
resistance to β-lactam antibiotics including methicillin (Baba et al., 2002; de Lencastre et
al., 2007). One of the most discriminative and utilized typing methods for S. aureus is
pulsed-field gel electrophoresis (PFGE) (Deurenberg and Stobberingh, 2008; Prevost et
al., 1991). The chromosomal DNA is digested by the restriction enzyme, Sma1, and the
DNA fragments of the bacteria are separated out by agarose gel electrophoresis. There
are currently eleven CA-MRSA PFGE types found in United States numbered as
USA100 to USA1100. Of these eleven types, USA300 and USA400 are responsible for
the majority of CA-MRSA disease seen in the United States and USA300 is replacing
traditional HA-MRSA in health care settings (Klevens et al., 2007). In 2005, the
incidence of invasive MRSA infections in the US was 31.8 out of 100,000, which is
greater than the incidence of all other invasive bacterial infections combined, and was the
cause of more deaths than HIV/AIDS that same year (Klevens et al., 2007).
CA-MRSA infections were first seen in children and then later in professional
football players and other athletes, prisoners, and men who have sex with men (Miller et
al., 2005; Otto, 2007). CA-MRSA is transmitted most frequently by direct contact with
the organism, most commonly mediated by skin-to-skin contact with a colonized or
infected individual or by contacting contaminated surfaces or items (Deleo et al., 2010),
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as opposed to HA-MRSA which is primarily caused by the patients’ colonizing strain
gaining access beyond the skin or mucosal barrier (Wertheim et al., 2005; Wertheim et
al., 2008).
The pathogenesis of CA-MRSA disease is much more aggressive than HA-MRSA
due to the numerous virulence factors associated with the strains that lyse cells and
destroy tissue, resulting in the entry of the bacteria into the blood stream. Coupled with
heightened virulence, CA-MRSA strains are highly resistant to standard antibiotic
therapy and many strains are multi-drug resistant. The majority of CA-MRSA isolates are
susceptible to non-β-lactam antibiotics (eg: clindamycin, tetracycline, doxycycline) but
determining the most appropriate treatment for a particular strain of unknown antibiotic
resistance profile is time consuming (Deurenberg and Stobberingh, 2008). Glycopeptides
(eg: vancomycin, teicoplanin) have been considered the treatment of choice for invasive
MRSA infections but concern has arisen due to the emergence and spread of strains with
reduced susceptibility to vancomycin (Simor et al., 2010). Linezolid, an oxazolidinone,
and daptomycin, a lipopeptide, are FDA-approved for invasive MRSA infections but
have not been shown to be more effective than vancomycin and are associated with
detrimental side effects (Deleo et al., 2010).
Due to the limitations of conventional antibiotic therapies against MRSA, it is
essential to develop new treatment options. One such option may be the targeting of S.
aureus virulence. Since virulence factors are involved in the pathogenesis of the infection
but not bacterial viability, targeting virulence could ameliorate the infection while the
lack of selective pressure would not promote resistance development to the treatment.
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This approach has focused efforts on understanding the virulence factors used by CAMRSA to cause disease and how they are regulated.

Bacterial Quorum Sensing
Intercellular communication between bacteria allows for coordinated activity
usually reserved for multicellular organisms (de Kievit and Iglewski, 2000). This
capacity for group behavior permits migration ability, adaptation of new modes of
growth, and coordinate production of virulence factors. The regulation of gene expression
in response to changes in cell-population density is referred to as quorum sensing and is a
cell-to-cell signaling mechanism. To date, there are four described quorum sensing
signaling systems that are grouped according to the signaling molecules, receptors, and
response regulators employed. A feature that is shared by all four types is the use of an
autoinducer pheromone that is released into the environment by the bacteria to sense the
density of the bacteria nearby. As the bacterial population increases, so does the presence
of the autoinducer, which leads to the alteration of bacterial gene expression, resulting in
changes including bacterial life cycle, metabolism, and phenotype (de Kievit and
Iglewski, 2000). The first system to be described was found in Vibrio fisheri, a Gramnegative, luminescent, marine bacteria (Miller and Bassler, 2001). The luciferase operon
of V. fisheri is regulated by two proteins, LuxI and LuxR. LuxI is responsible for the
production of the N-acyl-homoserine lactone (AHL), termed autoinducer-1 (AI-1) and
after synthesis, the AHL is free to diffuse across the membrane of the bacteria. As the
density of bacteria increases, so does the extracellular concentration of AHL until the
concentration is high enough that AHL freely diffuses back into the cell. The autoinducer
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is bound by a transcription factor LuxR which controls gene expression in the presence of
AHL (Devine et al., 1989). This system is used by numerous bacterial species including
Pseudomonas aeruginosa and Serratia marcescens (Parker and Sperandio, 2009).
Another signaling system utilizes the bacterial transcription factor LuxS that
modifies a compound, 4,5-dihydroxy-2,3-pentanedione (DPD), which cyclizes into
furanones in the presence of water. The furanone serves as the autoinducer, termed AI-2,
in this system and accumulates in the extracellular environment before binding to a
transporter and entering the bacterial cell where it is phosphorylated (Reading and
Sperandio, 2006). The phosphorylated AI-2 pheromone interacts with the transcriptional
repressor to lift repression of the operon, lsr (Taga et al., 2001). This system has been
observed in a wide range of Gram-positive and Gram-negative bacteria including
Escherichia coli, Salmonella typhimurium, and Streptococcus pyogenes, suggesting that
the AI-2 system represents a method of cross-species signaling (Xavier and Bassler,
2003).
A third mechanism of cell-to-cell signaling has thus far only been described in
Gram-negative bacteria. Observed in bacterial species including Shigella, Klebsiella, and
Salmonella as well as non-pathogenic E. coli (Walters et al., 2006), this system utilizes an
autoinducer of unknown structure (AI-3) and a two-component system consisting of
QseC, the sensor kinase, and QseB, the response regulator. The autoinducer is recognized
by QseC which autophosphorylates and transfers the phosphate to QseB. Phosphorylated
QseB then acts as a transcriptional regulator, activating downstream gene targets (Parker
and Sperandio, 2009).
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The fourth cell-to-cell signaling system, the AIP/agr system, is found exclusively
in Gram-positive bacteria (Parker and Sperandio, 2009). It was first identified in S.
aureus and is described in detail in the following section.

Quorum Sensing in S. aureus
Quorum sensing in S. aureus is controlled in part by the accessory gene regulator
(agr) which encodes a standard autoactivation circuit (Figure 1) (Novick and Geisinger,
2008). This type of quorum sensing is specific to Gram-positive organisms and has been
identified in Staphylococcus epidermidis and Enterococcus faecalis after originally being
characterized in S. aureus (Qin et al., 2001; Van Wamel et al., 1998; Yarwood and
Schlievert, 2003). The components of this autoregulatory quorum sensing system include
the signaling peptide AgrD, the secretory protein AgrB, responsible for the export and
processing of AgrD to its active form, AgrC, a histidine kinase, and AgrA, a response
regulator that detects AgrD levels and initiates the expression of the agr-dependent
virulence factors (Koenig et al., 2004). The target for AgrA is the activation of two
divergent promoters, P2 and P3. The activation of P2 drives the agrA,B,C,D operon while
P3 activation promotes RNAIII production, a regulatory RNA. The significance of the
agr locus in virulence has been illustrated in several experiments that demonstrate
considerable attenuation of virulence in S. aureus strains that have a defect in the agr
operon in multiple animal models of infection (Koenig et al., 2004). In this regard,
RNAIII production is essential for acute invasive infection at the entry site of an infection
(Rothfork et al., 2003b; Rothfork et al., 2004).
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Upon activation of the P2 promoter, the AgrD peptide is secreted through AgrB, a
transmembrane endopeptidase, where the peptide is cleaved, modified, and secreted
through AgrB with a thiolactone ring (Ji et al., 1997). This secreted structure is termed an
autoinducing peptide (AIP). There are four different types of AIP, which differ only in
amino acid composition and length. All AIP types possess the thiolactone ring which is
necessary for binding to and signaling through the AgrC sensor kinase receptor (Wright
et al., 2004). The different AIP molecules, classified as AIP1, 2, 3, or 4 serves to further
categorize the S. aureus strains as agr type 1, 2, 3, or 4 depending on which AIP the
bacteria secrete (Jarraud et al., 2000; Ji et al., 1997). The AIPs selectively bind to their
own cognate receptor and antagonize signaling when they bind to non-cognate receptors
(Lyon et al., 2002; Wright et al., 2005). USA300 and USA400, the predominant CAMRSA strains, are agr type 1 and agr type 3 respectively though all four types are
represented in human disease (Klevens et al., 2007).
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Figure 1. The agr quorum sensing operon in S. aureus
Propeptide AgrD is exported through AgrB, modified to become the thiolactone AIP. The
AIP signals through AgrC which phosphorylates the histidine kinase AgrA. AgrA acts on
the divergent P2/P3 promoter as well as the promoter for the toxin psmα. The P2
promoter encodes the agr signaling and response regulator proteins. The P3 promoter
induces transcription of the regulatory RNA, RNAIII, which acts on the promoters and
translation initiation regions of numerous genes to up-regulate secreted virulence proteins
important for invasion, and to down-regulate adhesins.
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The AgrC sensor histidine kinase is the receptor for AIP and after AIP binding, AgrC
dimerizes and autophosphorylates, transferring the phosphate to the response regulator
AgrA (Novick, 2003). AgrA is required for the activation of the two agr promoters (P2
and P3) and completing the autoactivation circuit (Novick et al., 1993). The binding
between AgrA and the P2 promoter is stronger than that between AgrA and the P3
promoter so autoactivation of the P2 operon precedes P3 activation (Cheung et al., 2004;
Koenig et al., 2004). AgrA binding to the P2 promoter leads to autoinduction of the agr
operon which is followed by the binding of AgrA to the adjacent and divergent promoter,
P3, which activates the transcription of the RNAIII regulatory RNA (Novick and
Geisinger, 2008).
S. aureus agr is unique in employing a regulatory RNA, RNAIII, as its effector as
opposed to the response regulator AgrA (Novick and Geisinger, 2008). RNAIII is a 514nt RNA molecule with a very complex secondary structure and regulates the expression
of many genes encoding expoproteins and cell-wall-associated proteins (Benito et al.,
2000). The structure of RNAIII is comprised of 14 hairpin stem loops, and the structure,
but not its sequence, is well conserved across several staphylococcal species (Benito et
al., 2000). The 3’ end of RNAIII acts to repress the transcription of the protein A gene
(SpA) while the 5’ and 3’ non-overlapping subregions are independently active in
stimulating the transcription of the alpha-hemolysin (hla) gene (Novick et al., 1993).
RNAIII acts as antisense, directly upregulating translation of alpha-hemolysin by
countering a secondary structure in the mRNA leader that blocks translation of the gene
(Morfeldt et al., 1995). RNAIII also acts on Rot (repressor of toxins), another major
transcription factor. Rot acts by upregulating translation of surface proteins while
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downregulating translation of secreted proteins, counter to RNAIII (Said-Salim et al.,
2003). RNAIII blocks translation of Rot by pairing with the translation-initiation region
(Geisinger et al., 2006). This allows RNAIII to downregulate colonizing factors such as
cell-surface protein genes and activate the transcription of virulence genes which code for
secreted toxins and proteases (George and Muir, 2007).
Production of RNAIII leads to a phenotypic switch in the bacteria from one of
colonization to an invasive phenotype (Figure 2). Colonization factors are molecules that
S. aureus uses to adhere to host epithelial cells and the formation of biofilm. These
factors include S. aureus surface protein A (SpA), a wall-anchored protein with four or
five domains that bind to the Fc region of IgG (Uhlen et al., 1984), clumping factor A
(clfA), the dominant fibrinogen-binding protein which is found on the surface of the
bacteria during stationary phase (O'Brien et al., 2002a),clumping factor B (clfB), which
also binds to fibrinogen but also cytokeratin 10, a major component of squamous cells
(O'Brien et al., 2002b; Wertheim et al., 2008), and fibronection binding protein (FnBP),
an important molecule in biofilm development (Houston et al., 2011). While these
colonization factors are important for adherence to tissues, invasive factors serve to lyse
cells causing damage to tissues and dissemination of the bacteria throughout the host.
While existing in the invasive phenotype, the bacteria produce molecules that
include proteases, hemolysins, and toxins which together serve to lyse cells and destroy
tissues which allow the bacteria to penetrate the tissues and enter the bloodstream.
Enterotoxins and toxic shock syndrome toxin (TSST) are produced at this stage which
contribute directly to the pathology seen in S. aureus infections (Yarwood and Schlievert,
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2003). Alpha-hemolysin, a cytolytic toxin responsible for the destruction of a wide range
of host cells with the exception of neutrophils (Valeva et al., 1997) is created as a result
of the upregulation of virulence factors. Alpha-hemolysin is secreted as monomers which
then associate into heptamers to form pores in the cytoplasmic membrane of target cells
causing lysis (Bhakdi and Tranum-Jensen, 1991). Another virulence factor produced in
response to quorum sensing is phenol soluble modulin α (PSMα), a cytolytic peptide that
is expressed abundantly in CA-MRSA strains (Queck et al., 2008; Wang et al., 2007).
The promoter of the psmα gene is directly activated by AgrA as opposed to other
virulence factors which are activated by RNAIII (Queck et al., 2008; Wang et al., 2007).
It has been postulated that the enhanced virulence of CA-MRSA strain USA300 may be
due to amplified production of PSMα and alpha hemolysin (Li et al., 2009).
A bicomponent leukotoxin, Panton-Valentine leukocidin (PVL), is an agrdependent leukocyte toxin unique to the earliest CA-MRSA strains. PVL may be
responsible for the emergence, transmission, or enhanced virulence of these specific
MRSA strains but presently, the exact target or mechanism is not clear (Gillet et al.,
2002; Graves et al., 2010). CA-MRSA strains, notably USA300, produce an abundant
amount of alpha-hemolysin, PSM α and PVL (Deleo et al., 2010) compared to HAMRSA strains. While the presence of PVL has been a hallmark in USA300 strains
causing human necrotizing pneumonia, mouse models of this disease using PVL deletion
mutant strains demonstrated no protection compared to infection with a wild type strain
(Bubeck Wardenburg et al., 2008; Gillet et al., 2002). Murine neutrophils are less
sensitive to the lytic effects of PVL than human neutrophils and this may provide an
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explanation for why PVL deletion mutants are not attenuated in mouse models of
infection. In contrast, rabbit neutrophils are similarly susceptible to PVL-induced
cytolysis as human and now experimental infections in rabbits are being used to
determine if PVL, like alpha-hemolysin and PSM α, contribute to invasive USA300
infections (Diep et al., 2010). LukGH is a newly identified two-component leukotoxin
that is secreted by USA300 (Ventura et al., 2010). LukGH synergizes with PVL to
enhance human neutrophil lysis as well as contributing to the lysis of neutrophils after
phagocytosis of the bacteria. The arginine catabolic mobile element (ACME) is another
operon of interest that USA300 most likely obtained from S. epidermidis. ACME
contains a gene for an arginine deiminase which allows the bacteria to better survive
acidic conditions and have increased fitness for transmission (Diep et al., 2006; Goering
et al., 2007). The role of ACME in pathogenesis is uncertain as comparison of an ACME
deletion mutant to a wildtype USA300 strains is attenuated in some animal models of
infection (Diep et al., 2008) but not in others (Montgomery et al., 2009). Therefore, the
virulence factors most directly related to the pathogenesis of both experimental and
human infections are alpha hemolysin and PSM α. The agr-regulated virulence factors
described above are used by CA-MRSA strains for invasion into host tissues and for
evasion of critical host defense elements. Because quorum sensing is essential for the
phenotypic switch of S. aureus from colonizing to invasive, inhibition of quorum
sensing, and thus the production of the virulence factors responsible for destructive
pathogenesis, is an intriguing option to pursue for possible treatment of S. aureus
infections.
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Figure 2. The phenotypic switch of S. aureus is density dependent
As the density of bacteria in an area increases, the higher concentration of extracellular
AIPs increases the chances of signaling through the AgrC receptor. Upon signaling
through AgrC, RNAIII expression will be activated which leads to a phenotypic switch
from a colonizing phenotype where adhesion genes were expressed, to an invasive
phenotype where virulence factors are being produced.
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Host Immunity to S. aureus Infection
The primary response of the host immune system to the presence of S. aureus is
innate system dominated, recruiting neutrophils and other phagocytes to the site of the
infection. Despite of the presence of S. aureus antibodies in most adults, the humoral
adaptive immune system plays a limited role in the control and clearance of the bacteria
and recovery from an S. aureus infection does not appear to confer protection against
subsequent infections (Holtfreter et al., 2010; Schaffer and Lee, 2008).
Components of S. aureus, including lipoteichoic acid (LTA) and capsular
polysaccharide, elicit the production of IL-8, a neutrophil recruiting cytokine, by
peripheral blood monocytes and epithelial and endothelial cells (Soell et al., 1995;
Standiford et al., 1994). Virulence factors such as toxic shock syndrome toxin-1 (TSST1)
and enterotoxins A and B, also stimulate IL-8 production by human monocytes
(Krakauer, 1998).
Host Toll-like Receptor 2 (TLR2) recognizes multiple pathogen-associated
molecular patterns (PAMPs) on the bacteria including LTA, lipoproteins, and
diacylglyceride (Kumar et al., 2011; Takeuchi et al., 2000)(Kumar et al., 2011; Kumar et
al., 2011; Takeuchi et al., 2000; Takeuchi et al., 2000)(Kumar et al., 2011; Kumar et al.,
2011; Takeuchi et al., 2000; Takeuchi et al., 2000). The host inflammasome, a set of
cytosolic proteins responsible for the activation of caspase-1 and the secretion of IL-1
cytokines, also recognizes PAMPs of S. aureus (Craven et al., 2009). Caspase-1
activation by the inflammasome requires either all three hemolysins (α-, β-, and γhemolysin) or α- and β-hemolysin in combination with bacterial lipoprotein released by
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S. aureus (Munoz-Planillo et al., 2009). The host system also has various ways to mark S.
aureus for phagocytic uptake. Deposition of complement fragments and accumulation of
fibrinogen and IgM antibodies on the surface of the bacteria efficiently opsonize S.
aureus, leading to the uptake of the bacteria by phagocytes and the influx of
inflammatory cells to the infection site (Laarman et al., 2010).
After phagocytosis of the bacteria, the neutrophils destroy the bacteria using
oxygen-dependent and oxygen-independent mechanisms (DeLeo et al., 2009).
Phagocytosis activates the NADPH oxidase which generates high levels of superoxide
which quickly dismutates into hydrogen peroxide and then other secondary reactive
oxygen intermediates including hypochlorous acid, singlet oxygen, and hydroxyl radicals
(Klebanoff, 1975; Rosen and Klebanoff, 1977). The importance of the NADPH oxidase
system and the production of reactive oxygen species is illustrated by the hereditary
disorder chronic granulomatous disease (CGD). CGD patients have a defect in the
NADPH oxidase which results in recurrent bacterial infections. This concept was also
illustrated specifically for S. aureus where it was shown that mice deficient in the
NADPH oxidase had increased susceptibility to invasive S. aureus infections indicating
the vital role of NADPH in host defense (Rothfork et al., 2004). The oxygen-independent
killing mechanism of the neutrophils is the fusion of the bacteria-containing phagosome
with azurophilic granules which contain numerous antimicrobial peptides and proteins
including α-defensins, cathepsins and azurocidin (Ganz et al., 1985; HIRSCH and
COHN, 1960). Antibacterial proteins are also important in defense against S. aureus on
the skin. The skin acts as a physical barrier against infection but keratinocytes possess
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multiple antimicrobial peptides including β-defensins and lipocalin which help to protect
against S. aureus on the skin and sterilization of wounded areas (Clarke et al., 2007;
Komatsuzawa et al., 2006). Neutrophils also contribute to host defense by the creation of
neutrophil extracellular traps (NETs) that are composed of chromatin threads with bound
histones and azurophilic granule proteins (Brinkmann et al., 2004). NETs are formed
following induction by chemokines, TLRs, and phagocytic receptors and results in the
mixing of the NET components as the nuclear envelope and granule membranes
disintegrate (Fuchs et al., 2007). NETs are released as the cell membrane breaks in a cell
death process that is distinct from both necrosis and apoptosis and is dependent on the
generation of reactive oxygen species by the NADPH oxidase to kill the bacteria (Fuchs
et al., 2007). NET entrapment of the bacteria contributes to extracellular killing by
antimicrobial peptides bound to the chromatin components.
The primary effectors of host defense against S. aureus include opsonization,
phagocytosis, and killing by antimicrobial peptides, all components of the innate system.
The adaptive system appears to primarily provide defense by antibody production utilized
for opsonization leading to phagocytic uptake and by antigen-specific CD4 Th1
lymphocytes (Breuer et al., 2005). During an infection, anti-staphylococcal antibodies
increase in the host serum, but this appears to provide limited control of the actual
infection (Holtfreter et al., 2010). The antibodies seen in patient sera are produced in
response to antigens involved in microbial adherence, the initiating event of the
infectious process, and are specific to the strain colonizing the patient (Vernachio et al.,
2003; Vernachio et al., 2006). Because of this specificity, the antibodies have little
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activity against the more virulent strains of S. aureus that cause invasive disease and
morbidity (Holtfreter et al., 2010). The Th17 subclass of lymphocytes enhance innate
phagocytic killing of S. aureus due to the production of IFN-γ and IL-17 by the cells
which are important for the activation of phagocytes and neutrophil migration (Lin et al.,
2009). Given that Th17 cells are important in various other bacterial infections (Reiner,
2007), they may play a larger and more regulatory role during S. aureus infections.
In addition to direct cidal activity or promotion of bacterial clearance, host
defense can also be provided by targeting virulence gene regulation. Importantly, both
host hemoglobin and apolipoprotein B have been recently described to protect against S.
aureus infection. The protective effect of hemoglobin (hemin) has been described as the
possible inhibition of AIP secretion by AgrB (Attia et al., 2010; Schlievert et al., 2007).
Apoliprotein B binds the secreted AIPs and prevents them from binding to the receptor,
AgrC, inhibiting quorum sensing and subsequent production of downstream virulence
factors (Peterson et al., 2008). These two host factors in addition to the inactivation of
AIPs by reactive oxygen species (Rothfork et al., 2004) are three ways the host inhibits
quorum sensing-dependent virulence factor production by S. aureus (Figure 3).
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Figure 3. Host control of quorum sensing
Three host factors are known to prevent quorum sensing including hemoglobin (hemin),
which inhibits AIP secretion through AgrB via membrane disruption, reactive oxygen
species from neutrophils which inactivate AIPs, and apolipoprotein B which can
sequester the AIP, inhibiting signaling through the AgrC receptor.
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Bacterial Escape of the Host Immune System
Although the host immune system possesses multiple and varied methods to quell
the infection and kill the bacteria, S. aureus has equivalent amounts of escape
mechanisms to evade the host immune system, avoid killing by phagocytes, and help
ensure a successful infection.
S. aureus possess numerous factors that compromise the effectiveness of the first
line of defense of the host, macrophages and neutrophils. The first evasion tactic is to
avoid interaction with the phagocytes completely. At the onset of bacterial growth, host
cells produce chemoattractants to recruit neutrophils to the site of infection. Neutrophils
respond to the complement proteins C3a and C5a as well as bacteria-secreted formylated
peptide, FMLP. Approximately 60% of S. aureus strains secrete the chemotaxis
inhibitory protein of staphylococci (CHIPS) to inhibit the neutrophil response by binding
to and blocking the formyl peptide receptor and the C5a receptor that are found on the
neutrophil surface (de Haas et al., 2004; Foster, 2005b). The bacteria also express the
extracellular adherence protein (Eap) which binds to ICAM-1, a ligand on the surface of
endothelial cells. This binding, in turn, blocks the binding of ICAM-1 with LFA-1 found
on the surface of neutrophils, preventing adhesion and extravasation of the neutrophils
through the endothelial barrier (Chavakis et al., 2002; Sun, 2009).
S. aureus also has tactics to avoid phagocytosis through the use of varied surfaceassociated anti-opsonic proteins. The host complement system can be activated in three
ways but all pathways converge at the central step of the activation of complement
molecule C3. Activation of C3 results in the deposition of C3b molecules on the surface
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of the bacteria which is essential for activation of complement. Staphylococcus
complement inhibitor (SCIN), is secreted by S. aureus, and is capable of blocking all
complement pathways (Rooijakkers et al., 2005a; Rooijakkers et al., 2005b). SCIN
inhibits the production of C3b, the amplification loop which follows, and ultimately the
formation of the neutrophil chemoattractant C5a (Jongerius et al., 2010; Rooijakkers et
al., 2005a). SCIN also dimerizes the convertase enzymes, which leads to impaired
binding of the convertase to the complement receptor resulting in the inhibition of
phagocytosis (Jongerius et al., 2010). The extracellular fibrinogen-binding protein (EfB)
and staphylococcal binding protein (Sbi) also inhibits complement activation by binding
to C3 preventing deposition and accumulation of C3b on the bacteria (Burman et al.,
2008; Lee et al., 2004). Clumping factor A (clfA), the dominant fibrinogen-binding
protein found on the surface of the S. aureus during stationary phase, protects the bacteria
against opsonization and phagocytosis by binding fibrinogen (O'Brien et al., 2002a). In
addition, clfA increases the cleavage of C3b into the inactive form, iC3b, by complement
factor 1 (Hair et al., 2010). Similar to clfA, clumping factor B (clfB) and fibronectin
binding protein (FnBP) bind to fibrinogen providing the same protection as clfA but in
the exponential phase of bacterial growth (Ni Eidhin et al., 1998; Wertheim et al.,
2008).The capsule of the bacteria also serves to protect against opsonization and
subsequent phagocytosis (Thakker et al., 1998). The excretion of the protease
staphylokinase activates human plasminogen into plasmin which has the ability to cleave
both surface-bound IgG and C3b (Bokarewa et al., 2006; Rooijakkers et al., 2005c). S.
aureus surface protein A (SpA) is a wall-anchored protein with four or five domains and
each of these domains bind to the Fc regions of IgG (Uhlen et al., 1984). This binding
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results in the coating of the outside of the bacteria with IgG molecules in the incorrect
orientation to be recognized by the Fc receptor of the neutrophils which protects against
phagocytosis.
If the phagocyte is able to engulf the bacteria, the arsenal of S. aureus comprises
more survival tactics to avoid killing by the neutrophil. All S. aureus species are catalase
positive, another device the bacteria uses to thwart killing by neutrophils. Catalase
inactivates hydrogen peroxide and free radicals that comprise the respiratory burst of the
neutrophil following phagocytosis allowing the bacteria to persist inside the phagosome
(Palazzolo-Ballance et al., 2008). S. aureus survival in the neutrophil is also facilitated by
the ability of the bacteria to prevent fusion of the phagosome with azurophilic granules.
S. aureus is able to escape the phagosome and multiple rapidly in the intracellular
environment of the neutrophil (Gresham et al., 2000). The carotenoid pigment that gives
S. aureus its hallmark gold color also plays an important role in protecting the bacteria
from neutrophil killing by scavenging oxygen free radicals (Clauditz et al., 2006; Liu et
al., 2005). S. aureus also secretes staphylokinase, which binds host defensins and
stimulates the degradation of IgG and complement molecule C3, and aureolysin, a
metalloprotease that cleaves and inactivates the defensin peptide cathelicidin LL37
(Jongerius et al., 2009; Sieprawska-Lupa et al., 2004)(Foster, 2005a; Jongerius et al.,
2009; Jongerius et al., 2009; Jongerius et al., 2009; Jongerius et al., 2009; SieprawskaLupa et al., 2004; Sieprawska-Lupa et al., 2004).
S. aureus secretes many lytic factors which also help protect the bacteria from the
host immune system by damaging or killing leukocytes. Alpha-hemolysin, a cytolytic
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toxin, forms pores in the cytoplasmic membrane of target cells causing lysis, and PantonValentine leukocidin (PVL), a bicomponent leukotoxin, another pore-forming toxin, are
two factors of note (Bhakdi and Tranum-Jensen, 1991; Gillet et al., 2002; Graves et al.,
2010). Another important secreted lytic factor is α-type phenol soluble modulin (PSMα)
which recruits and lyses neutrophils (Li et al., 2009). The multiple evasion mechanisms
evolved by this pathogen illustrate why clearance by the host immune system alone is
difficult and sometimes not sufficient.

Current Therapeutics Against S. aureus
Antibiotic resistance is an increasing complication in the ability to combat S.
aureus infections. As early as the 1940s, cases of penicillin resistance were identified in
hospitals and by the 1950s, these strains were causing infections outside of the hospital
setting (Chambers and Deleo, 2009). Methicillin resistant strains emerged in the hospital
by 1961 and by the late 1990s appeared in the community, afflicting individuals who had
no predisposing risk factors for infection and causing severe infections including
necrotizing pneumonia and necrotizing fasciitis (Miller et al., 2005). With the exception
of the narrow-spectrum drugs daptomycin and linezolid, there have been no new classes
of clinically relevant antibiotics discovered in 40 years which illustrates a looming threat
of a postantibiotic era (Clatworthy et al., 2007). Traditional antibiotics work by either
killing the bacteria or inhibiting growth. These bacteriocidal or bacteriostatic agents
inhibit bacterial functions such as cell wall synthesis, DNA replication, RNA
transcription, and protein synthesis that are essential for in vitro, logarithmic growth
(Clatworthy et al., 2007). Unfortunately, these strategies place a selective pressure on the
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bacteria, leading to mutations and the development of antibiotic-resistant strains that are
being seen.
A staphylococcal vaccine would be an ideal way to target the infection and
protect the populations most at risk. However, attempts at vaccine creation have, thus far,
been unsuccessful. Vaccine production against S. aureus has proven to be a challenge for
many reasons. First, S. aureus has many membrane-bound surface molecules and
secreted proteins with redundant functions which makes the targeting of one molecule by
a vaccine easily overcome by the bacteria compensating with expression of a different
protein with the same function (Shinefield and Black, 2006). Additionally, S. aureus has
multiple strategies to escape from the host innate immune system (Foster, 2005a; Foster,
2009; Horswill and Nauseef, 2008), has the ability to persist insulated in biofilms
(Yarwood et al., 2004), and can survive as small colony variants (Schaffer and Lee, 2008;
Vaudaux et al., 2006).
Active immunization was attempted by Nabi Biopharmaceuticals which created
StaphVAX, a bivalent vaccine that combined vaccination against capsular polysaccharide
serotypes (CP) 5 and 8. This vaccine failed in phase III testing most likely due to capsulenegative, highly virulent clinical isolates and the circumstance that actively replicating
staphylococci are do not express capsule (O'Riordan and Lee, 2004; Schaffer and Lee,
2008). Passive immunization has also been attempted by administering neutralizing
antibodies against specific S. aureus-virulence factors. Clumping factor A was one of
these products (Veronate, Inhibitex) where human immunoglobulin was collected from
donors with high antibody titers against the S. aureus adhesin. The product failed in
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phase III trials possibly due to low affinity or avidity to the target antigen (DeJonge et al.,
2007). Another related product is a monoclonal antibody to clumping factor A
(Aurexis/tefibazumab, Inhibitex) which has completed phase II trials. Other S. aureusvirulence factors that are currently in the pipeline as possible future targets for
therapeutics include CP5 and CP8 (AltaStaph, Nabi), ABC transporter (Aurograb,
NeuTec), and lipoteichoic acid (Pagibaximab, Biosynexus) (Schaffer and Lee, 2008).
Vaccines created from exotoxins have also been tried with some success. Alphahemolysin, a pore-forming toxin secreted by S. aureus is a major proponent of host tissue
damage seen in infections. A mutant-alpha hemolysin (H35L) that was non-toxic and
non-hemolytic was created by site-directed mutagenesis and antibodies against this
mutant toxin had protective effects in mice that were passively immunized (Menzies and
Kernodle, 1996). The H35L mutant was also protective in a lung infection model where
the mice that were immunized with the protein prior to intranasal challenge with S.
aureus exhibited reduced lethality (Bubeck Wardenburg and Schneewind, 2008).
Immunization with mouse monoclonal antibodies to the H35L mutant were also shown to
be protective (Ragle and Bubeck Wardenburg, 2009). These findings suggest that the
inhibition of a single virulence factor that predominates in tissue injury may be sufficient
to protect the host from a potentially lethal S. aureus infection.
This approach to antimicrobial therapies of targeting of bacterial virulence factors
as opposed to growth has been gaining enthusiasm and promise. Removing the virulence
properties of pathogens without altering growth would provide a reduced selective
pressure environment for drug resistant mutant strains (Cegelski et al., 2008) as well as a

26

less virulent pathogen in which the host may be able to clear by way of its own immune
effectors.

High Throughput Screening for Identification of Small Molecule Inhibitors
One strategy emerging for modern drug discovery is high-throughput screening. It
comprises the screening of large chemical libraries for activity against biological targets,
various intracellular and extracellular molecules, and does so by the use of automation,
miniaturized assays, and large-scale data analysis (Mayr and Bojanic, 2009)(Kool et al.,
2010). Cell-based screening specifically has become an integral aspect of drug discovery,
having the advantage of testing the effect of compounds against molecular targets within
living cells (Black et al., 2011).

Targeting Bacterial Virulence
Bacteria utilize a broad array of virulence factors to cause disease in the host.
Adhesins facilitate colonization after binding to host cells, toxins can kill or alter signal
transduction in host cells, and secretion systems deliver bacterial effectors (Rasko and
Sperandio, 2010). All of these pathways represent areas that could be targeted for
therapeutic intervention and inhibition. Targeting virulence in bacteria provides many
advantages over traditional antibiotics. The most obvious being that when the targeted
virulence factor is not essential for in vivo survival, selective pressure should not be an
issue since growth is not being inhibited. If mutations develop that give rise to resistance,
the fitness of the bacteria will not be affected. Also, alterations of the host microbiota that
are associated with current antibiotic therapies would be avoided due to the specificity of
the virulence-targeting drug. The preservation of the host flora would reduce the risk of
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secondary infections and colonization with the drug-resistant organisms (Barczak and
Hung, 2009; Clatworthy et al., 2007).
To effectively colonize the host and promote disease, bacterial adhesins are
essential in the bacterial attachment to host cells. In both Gram-negative and Grampositive bacteria, pili or fimbrae mediate this attachment. Adhesion can be blocked in an
E. coli infection by saturating the exposed carbohydrate-binding sites on the pili with
mannose derivatives and thus resulting in lower bacterial burden and invasion in a mouse
model of cystitis (Wellens et al., 2008). In Gram-positive organisms, sortase, a necessary
component for adhesion to host cells accomplished by catalyzing the assembly of surface
proteins, also serves as a promising drug target (Maresso and Schneewind, 2008). Sortase
A of S. aureus has been targeted in multiple studies where different small molecule
inhibitors of the surface enzyme have been described (Chenna et al., 2008; Oh et al.,
2004). Biofilm production, seen in bacteria such as S. aureus and P. aeruginosa, could
also be inhibited by the targeting of bacterial adhesin molecules which would be
beneficial given the notorious drug tolerance of bacteria in biofilms (Bayles, 2007).
Another popular target of these anti-virulence therapies is the production of the
toxins themselves that have a direct role in causing the disease. Inhibiting toxin
transcription, expression, and function have shown great promise as effective therapeutics
(Barczak and Hung, 2009). Cholera toxin, in addition to toxin coregulated pilus, was
inhibited by a small molecule in a mouse model of cholera infection. This compound,
virstatin, directly inhibited ToxT dimerization, a transcription factor essential for
virulence factor expression, which resulted in blocked intestinal colonization of mice
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with V. cholerae (Hung et al., 2005; Shakhnovich et al., 2007). Bacillus anthracis secrets
a zinc-dependent metalloprotease toxin known as anthrax lethal factor, one of the two
toxins critical for anthrax pathogenesis, that contributes directly to cell death. Small
molecule inhibitors were identified, specifically a hydroxamate derivative, to interact at
the lethal factor active site and inhibit virulence of this lethal toxin (Panchal et al., 2004;
Schepetkin et al., 2006; Shoop et al., 2005). Recently, five non-hydroxamic acid small
molecules were identified as new lethal factor inhibitor scaffolds by a novel in silico
high-throughput virtual screening assay (Chiu et al., 2009), furthering the interest and
enthusiasm in this new direction of anti-virulence therapeutics.
The delivery system of these toxins is another area that has been investigated for
its potential as a target. The type III secretion system (T3SS), used by many Gramnegative pathogens including E. coli, Pseudomonas aeruginosa, and species of Yersinia
to inject the bacterial effectors into the cytosol of the host cell, is one such system that
has been targeted (Cegelski et al., 2008). In Yersinia pseudotuberculosis, small molecule
inhibitors of the T3SS prevented the effector proteins of the pathogen, Yersinia outer
proteins, from being translocated into the host cells (Harmon et al., 2010; Kauppi et al.,
2003; Nordfelth et al., 2005). This secretion system was again the target of inhibition in a
species of Chlamydia because a small molecule inhibitor of T3SS inhibited intracellular
replication and infectivity of C. trachomatis (Muschiol et al., 2006).
The quorum sensing systems of bacteria are also very attractive targets for
therapeutic intervention owed, in part, to the fact that these systems are not usually found
in eukaryotic hosts. Several strategies have been developed to target the signaling system
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which is responsible for cell-to-cell signaling and synchronized downstream formation of
virulence factors. An example of this has been demonstrated for Pseudomonas
aeruginosa. P. aeruginosa utilizes a MvfR-dependent quorum-sensing regulatory
pathway which controls the expression of key virulence genes. The introduction of
anthranilic acid analogues to the pathogen inhibits 4-hydroxy-2-alkylquinolines (HAQ)
biosynthesis and disrups MvfR-dependent gene expression and has shown great promise
in a mouse model measured by improved mouse survival and decreased bacterial spread
(Lesic et al., 2007). In enterohemorrhagic E. coli, S. typhimurium, and F. tularensis,
QseC, is a membrane kinase that is essential for quorum sensing upon recognizing the
bacterial autoinducer 3 signal or host adrenaline or noradrenaline hormones. Upon
sensing, QseC increases its autophosphorylation and activates a virulence gene regulation
cascade. This pathway was inhibited by a small molecule, identified by a high-throughput
screening assay, that binds to QseC , preventing it from binding to its cognate signals and
activating the expression of virulence genes (Rasko et al., 2008). Due to homology of
QseC in many Gram-negative bacteria, this inhibitor demonstrated effectiveness in a
wide range of pathogens lending credence to the possibility of a broad spectrum
therapeutic for Gram-negative bacteria.
Two-component regulatory systems are necessary for quorum sensing in Grampositive bacteria. In S. aureus, the global regulator, agr, responds to bacterial density and
controls virulence gene expression when activated by autoinducing peptides (AIP)
(Novick and Geisinger, 2008). The AIP binds to and activates a membrane-bound
histidine kinase, AgrC, which dimerizes and results in the activation of target genes and
the synthesis of additional AIP (George and Muir, 2007). The four AIPs identified in S.
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aureus each bind selectively to their cognate AgrC receptor and quorum sensing is
inhibited when AIPs bind to their non-cognate receptor (Wright et al., 2005). This
suggests that S. aureus infections may be ameliorated by the synthesis and introduction of
competing AIPs which would result in inhibited bacterial signaling (Wright et al., 2005).
Another antagonist of S. aureus virulence is cyclic dipeptides produced from
Lactobacillus reuteri (Li et al., 2011).The dipeptides inhibit agr dependent-quorum
sensing and toxin production in vitro as well as inhibiting signaling through other sensorregulators used by S. aureus to regulate gene expression, but whether this would provide
protection in vivo has not been addressed.
Although not classified in one of the above groups, certain other small molecule
inhibitors of virulence are of note due to their anti-staphylococcal activity. FtsZ is a
bacterial cytoskeleton protein that is involved in cell division. A small synthetic
molecule, PC190723, inhibits FtsZ and prevents cell division of the bacteria and by
acting as a traditional antibiotic it cures mice infected with a lethal dose of S. aureus
(Haydon et al., 2008; Singh and Panda, 2010). A different small molecule, 1835F03, was
found to inhibit wall teichoic acid biosynthesis. The molecular target of the drug, TarG, is
the transmembrane component of the ABC transporter that exports cell wall teichoic
acids to the surface of the cell (Suzuki et al., 2011; Swoboda et al., 2009). The pigment
that gives S. aureus its hallmark color has also served as a target for inhibition.
Staphyloxanthin is a carotenoid pigment that protects the bacteria from reactive oxygen
species by quenching free radicals (Clauditz et al., 2006; Liu et al., 2005). Synthase CrtM
is essential in the biosynthesis pathway of staphyloxanthin. Treatment of S. aureus with
phosphonosulfonate BPH-652, a cholesterol-lowering drug, inhibited CrtM which led to
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decreased survival of the bacteria when exposed to hydrogen peroxide and to the
phagocytic cells in whole blood (Liu et al., 2008). A small molecule inhibitor of S.
aureus ribonuclease P (RnpA) a molecule essential in mRNA degradation, inhibits
cellular mRNA turnover. The RnpA inhibitor effected the production of virulence factors
due to the growth-phase dependent nature of virulence factor expression and exhibited
protection in an acute lethal mouse model of infection (Olson et al., 2011). Thus,
numerous targets have been developed for high throughput screening to advance drug
discovery for the treatment of bacterial infections. Importantly for the work described
here, the application of this strategy to quorum sensing regulated virulence by S. aureus
has not been described.

Summary and Hypothesis
The increasing emergence of methicillin resistant Staphylococcus aureus
infections (Chambers and Deleo, 2009; Klevens et al., 2007), particularly those caused by
a single clone (PFGE type USA300), coupled with the slowing of antibiotic discovery
and challenges in effective vaccination makes research into novel therapies a priority
()(Garcia-Lara et al., 2005a; Garcia-Lara et al., 2005b; Garcia-Lara et al., 2005b; Lowy,
2007). One evolving strategy to treat these antibiotic resistant infections is to develop
drugs that target bacterial virulence factors but not bacterial growth (Cegelski et al.,
2008; Clatworthy et al., 2007; Rasko and Sperandio, 2010). This approach is postulated
to limit the development of resistance while enhancing host defense by permitting
immune effectors to kill and clear the pathogenic bacteria rendered avirulent by the drug.
While this approach has had success in animal models of primarily Gram-negative
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bacterial infection (Cegelski et al., 2008; Clatworthy et al., 2007; Rasko and Sperandio,
2010), it has not been pursued for treatment of MRSA infection.
The virulence factors identified to date as essential for invasive MRSA infection
are globally regulated in part by a quorum sensing operon, agr (George and Muir, 2007;
Novick and Geisinger, 2008; Yarwood and Schlievert, 2003). Our work identifying
apolipoprotein B as an innate barrier that antagonizes agr signaling demonstrates that
host defense against an invasive infection can be accomplished by blocking agr signaling
(Peterson et al., 2008). Our work focuses on two small molecule inhibitors, CID# 2333
and CID# 3243271, identified in a screen of over 20,000 compounds for antagonism of
agr signaling. We hypothesized that screening small molecules for inhibition of agr
signaling could contribute to drug discovery by providing optimal host defense against
quorum sensing dependent S. aureus infections.

33

CHAPTER 2
METHODS
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Reagents
Synthetic AIPs were generated as follows and stored in DMSO at -80°C: cyclic AIP1,
AIP2, AIP3, and AIP4 were synthesized by Commonwealth Biotechnologies, Inc.,
Richmond, VA, and Biopeptide Co., Inc. San Diego, CA. The following reagents were
obtained

as

indicated:

glycine,

bovine

serum

albumin

(BSA)

3,3′-

dipropylthiacarbocyanine iodide (DiOC2), bovine catalase, clindamycin, Roswell Park
Memorial

Institute

(RPMI),

benzbromarone,

2-hydroxypropyl

β-cyclodextrin,

hydroxypropyl methylcellulose, 1M NaOH (Sigma-Aldrich, St. Louis, MO), H2O2
(EMD-Calbiochem, Gibbstown, NJ), Triton X-100 (Fischer Biotech), Hepes, Dulbecco’s
Modified Essential Media (DMEM) (Gibco), Casamino acids (Difco), Propidium iodide
(Anaspec, Inc), savirin (Chem Div, San Diego, CA), BBL trypticase soy broth (TSB),
BBL stacker plates with trypricase so agar with 5% sheep blood (Becton Dickinson and
Company, Sparks, MD), rabbit erythrocytes (CS1081, Colorado Serum Company).
Benzbromarone and savirin were solubilized in DMSO (1 mg/ml) for in vitro
experiments.

Bacterial Strains
S. aureus strains used in these studies were as follows: ALC 1743 (RN6390 containing
reporter agr::P3-gfp) and Newman-GFP (agr group 1 Newman containing reporter
agr::P3-gfp) were provided by Dr. Ambrose Cheung, Dartmouth School of Medicine.
Strain 502A (agr group 2 clinical isolate) was purchased from ATCC. USA400 1560
strain was provided by Dr.Francoise Perdreau-Reminginton (UCSF). USA300 strain
LAC, its ∆agr mutant, and USA400 strain MW2, were provided by Dr. Michael Otto
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(NIAID). AH1677 (agr group 1 LAC containing reporter agr::P3-gfp), AH430 (agr
group 2 502A containing reporter agr::P3-gfp), AH1747 (agr group 3 MW2 containing
reporter agr::P3-gfp), and AH1872 (agr group 4 containing reporter agr::P3-gfp) were
provided by Dr. Alexander Horswill (University of Iowa). Clinical isolate samples were
obtained from the Veterans Affairs Hospital, Albuquerque, NM.

Preparation of Bacterial Cultures
Primary stocks of all bacterial strains were prepared as followed: 25 ml of Trypticase Soy
Broth (TSB), (prepared with 4 μg/ml tetracycline for the LAC Δagr strain) in a 50 ml
tube was inoculated with a colony from an original culture or a 1:2500 dilution of
original stock was loosely capped and incubated with shaking (200 rpm) overnight at
37°C. After overnight incubation, cultures were pelleted by centrifugation at 3000 rpm
for 4 minutes at 4oC and washed twice with 10 ml of saline. The bacteria were
resuspended in 5 ml of TSB and two dilutions of 1:84 were made in two 50 ml Falcon
tubes containing TSB and tetracycline if necessary (LAC ∆agr) The tubes were loosely
capped and the cultures were incubated at 37°C with shaking (200 rpm) for 6 hours after
which the cultures were centrifuged and each tube was washed with 5 ml saline. The
cultures were washed again and combined with 10 ml of saline and centrifuged a final
time. The bacterial pellet was resuspended with 2 ml of TSB/ 10% glycerol, and kept on
ice while sonicating twice for 5 seconds each time. The bacterial stock was then aliquoted
into cryovials at a volume of 100 µl and stored at -80°C.
To generate synchronized early exponential phase, nonfluorescent (where
applicable) bacteria, frozen stocks were cultured in Trypticase soy broth (TSB) at a
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1:2500 dilution in one 50 ml Falcon tube overnight at 37°C with shaking at 200 rpm. The
overnight culture was washed twice with 20 ml volumes and once with a 10 ml volume of
sterile saline and then diluted 1:1000 in TSB in a 50 ml Falcon tube. The tube was
loosely capped and incubated for 2 hours at 37oC with shaking at 200 rpm. After two
hours, the culture was centrifuged as described, washed as before, and then diluted 1:84
into two tubes for 2 additional hours of incubation followed by a 1:125 dilution into four
tubes for two final hours of incubation with washing in between. At the end of the three
two hour growth periods, the cultures were washed with saline and combined into one
tube. The bacteria were then resuspended in 2 ml of TSB/10% glycerol, placed on ice and
sonicated for two intervals of five seconds each. The cultures were aliquoted into
cryovials at a volume of 100 µl per vial and stored at -80oC. The titer of each stock was
determined after the vials had been frozen for at least 30 minutes. The bacterial pellet of
four vials was resuspended by adding sterile saline to a volume of 1ml each and
centrifuging in a microcentrifuge at 4oC for 4 minutes at 12,500 rpm to wash out the
glycerol. The supernatant was discarded and the pellets were resuspended in 1 ml of fresh
saline. The vials were each sonicated for three intervals of two seconds and then serial
dilutions of the bacteria were plated on sheep blood agar plates to determine the titer of
the stock.

Bacterial Promoter Activation Assay
Early exponential phase bacteria (2 x 107/ml TSB) containing plasmid agrP3 driving GFP
expression were incubated in polystyrene tubes with or without 50 nM of the
corresponding synthetic AIP, benzbromarone (5 µg/ml), savirin (5 µg/ml) or vehicle
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control at 37oC with shaking (200rpm) for a designated amount of time. After incubation,
bacteria were centrifuged (3000 rpm, 4 minutes, 4oC), decanted, washed with phosphate
buffered saline (PBS) with 0.1% Triton X-100, fixed with 1% paraformaldehyde
containing 25 mM CaCl2, sonicated, and then evaluated for GFP expression by flow
cytometry (Accuri C6, Accuri Cytometers, Inc., Ann Arbor, MI) and measured as the
mean channel ﬂuorescence (MCF).
An alternate bacterial promoter assay was performed during overnight culture in the
absence of exogenous AIP and represented the bacteria/drug solution that was
administered in the in vivo experiments. One milliliter solutions consisting of early
exponential phase bacteria (~3 x 109) containing the GFP plasmid on the P3 promoter
(500 µl), 1 mg/ml savirin or vehicle control (100 µl), and TSB (400 µl) were made up
and 50 µl aliquots of each solution was added to each well of a 96 well polystyrene
micotiter plate. The plate was wrapped in foil and incubated with shaking (200 rpm,
37oC) overnight (18 hr). After incubation, 100 µl of 1% paraformaldehyde containing 25
mM CaCl2 was added to fix the cells and evaluation of GFP expression was determined
using flow cytometry (Accuri C6, Accuri Cytometers, Inc. Ann Arbor, MI).

Quantitative RT-PCR
Early exponential phase bacteria (2 x 107) were cultured in 1ml volumes at 37oC with
shaking (200 rpm) and with the indicated AIP and drug treatment for the designated
amount of time. Bacterial RNA for various targets was quantified relative to 16S RNA
using a probe-based assay as described with minor modifications (Sawires and Gresham,
2008). Bacterial RNA was isolated and purified using the Qiagen RNAprotect Bacteria
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Reagent and RNeasy Mini Kit, Protocol 3 using mechanical (sterile 0.1 mm zirconia
silica beads, Biospec, Bartlesville, OK) and enzymatic disruption by Proteinase K
(Qiagen, Valencia, CA). The RNA was purified using a column-based purification.
DNase treatment was used to remove contaminating DNA from the column. cDNA was
generated from the purified RNA using a high capacity cDNA-reverse transcriptase kit
with an accompanying RNase inhibitor (Applied Biosystems, Foster City, CA) and a
PTC-100 thermocycles (MJ Research Inc, Watertown, MA). Thermal cycling conditions
were described in the kit instructions were as follows: 10 minutes at 25oC, 120 minutes at
37oC, 5 minutes at 85oC, hold at 4oC. Quantitative PCR was performed using an
ABI7500 Real-Time PCR system with Taqman Gene Expression master mix, ROX
probe/quencher, and appropriate primer sequences (Applied Biosystems). Experiments
were performed in duplicate or triplicate and samples were assayed in triplicate. Relative
quantification of S. aureus targets was determined by the change in target gene
expression relative to 16S gene expression. Cycling conditions were 2 minutes at 50oC,
10 minutes at 95oC, and 40 cycles of 15 seconds at 95oC with 1 minute at 60oC. The
primer-probe sequences used for targets investigated were as follows:

RNAIII forward primer

5ʹ-AATTAGCAAGTGAGTAACATTTGCTAGT-3ʹ

RNAIII reverse primer

5ʹ-GATGTTGTTTACGATAGCTTACATGC-3ʹ

RNAIII probe

5ʹ-6-FAMAGTTAGTTTCCTTGGACTCAGTGCTATGTATTTTTCTT-BHQ-2-3ʹ

psmα forward primer

5ʹ-TATCAAAAG-CTTAATCGAACAATTC-3ʹ

psmα reverse primer

5ʹ-CCCCTTCAAATA-AGATGTTCATATC-3ʹ
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psmα probe

5ʹ-6-FAMAAAGACCTCCTTTGTTTGTTATGAAATCTTATTTACCAGBHQ-2-3ʹ

hla forward primer

5ʹ -ACAATTTTAGAGAGCCCAACTGAT-3ʹ

hla reverse primer

5ʹ-TCCCCAATTTTGATTCACCAT-3ʹ

hla probe

5ʹ-6-FAMAAAAAGTAGGCTGGAAAGTGATA-BHQ-2-3ʹ

PVL forward primer

5ʹ-CACAAAATGCCAGTGTTATCCA-3ʹ

PVL reverse primer

5ʹ-TTTGCAGCGTTTTGTTTTCG-3ʹ

PVL probe

5ʹ-6-FAMAGGTAACTTCAATCCAGAATTTATTGGTGTCCTATC-BHQ-2-3ʹ

16S forward primer

5ʹ-TGATCCTGGCTCAGGATGA-3ʹ

16S reverse primer

5ʹ-TTC-GCTCGACTTGCATGTA-3ʹ

16S probe

5ʹ-6-FAMCGCTGGCGGCGTGCCTA-BHQ-2-3ʹ

Microarray analysis
To compare the transcript levels of LAC USA300 and the ∆agr mutant in the presence or
absence of savirin, the bacteria were grown for 5 hr with AIP1 (50 nM) or an equivalent
amount of DMSO as the vehicle control and processed for microarray analysis as
described (Voyich et al., 2005). S. aureus cDNA was hybridized to custom Affymetrix
GeneChips, RMLChip7a520611F, containing 100% of the USA300 genome. Samples
were scanned according to standard GeneChip protocols and each experiment was
repeated in triplicate. The data were evaluated using GeneSpring.
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Viability Assays
Benzbromarone: LAC USA300 (2 x 107) was incubated at 37oC with shaking (200 rpm)
in the presence or absence of benzbromarone (5 µg/ml or 10 µg/ml) or vehicle control.
Viability was determined by removing aliquots at desired timepoints of growth and
dilutions of the cultures were plated on blood agar plates and enumerating the viable
colony forming units (CFU).
Savirin: LAC USA300 (1 x 106) was incubated in 5ml TSB in the presence or absence of
savirin (5 µg/ml). The bacteria were centrifuged, decanted, and resuspended in 5ml fresh
TSB with new addition of drug every 24 hours. This procedure was repeated for 3 days.
Growth was determined by plating out dilutions of the culture on sheep blood agar every
24 hr and enumerating colony forming units.

Alpha Hemolysin Assay
Alpha hemolysin was measured in 0.45 µm filtered cultured supernatant for bacterial
strains grown overnight in TSB in the presence or absence of benzbromarone (5 µg/ml)
or savirin (5 µg/ml). Alpha hemolysin was measured as described using rabbit
erythrocyte lysis (Bernheimer, 1988)(Black et al., 2011)Black et al., 2011) as described
(Peterson et al., 2008). Rabbit erythrocytes (CS1081, Colorado Serum Company) were
washed in PBS twice by centrifugation at 3200 rpm for 10 minutes at 4oC to remove the
Alsever’s preservation buffer. Erythrocytes were then resuspended in PBS to a final
concentration of 4% erythrocytes. Serial dilutions of the sample supernatants were mixed
in equal volumes with the erythrocyte suspension in a 96 well round bottom plate and
incubated for 1 hour at 37oC. After the incubation, the plate was centrifuged for 3
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minutes at 3800 rpm at 4oC to pellet the unlysed erythrocytes and the supernatants were
transferred to a new 96 well plate then read on a spectrophotometer at a wavelength of
450 nm. The lysis by the individual supernatant samples was compared to the total lysis
of erythrocytes that resulted from mixing equal volumes of the erythrocyte suspension
and PBS/0.1% Triton. One unit of hemolytic activity was defined as the amount of
bacterial supernatant able to liberate half of the total hemoglobin from the erythrocytes.

Staphyloxanthin Production and Extraction Assay
Primary cultures of LAC USA300 or LAC USA300 ∆agr mutant (10 µl) were cultured in
25 ml TSB for 48 hr in the presence of benzbromarone (5 µg/ml). Aliquots of 3 ml were
removed every 12-24 hr, centrifuged (3000 rpm, 4oC, 4 minutes), decanted, and images
of the pigmented pellets were taken. Quantification of staphyloxanthin production was
measured as described (Resch et al., 2005). At timepoints of 24, 32, and 48 hr, 5 ml
cultures were removed and equalized to an OD600 to ~1.0. Bacteria were centrifuged,
decanted, and treated with lysostaphin (3 µg/ml) diluted in PBS (total volume of 100 µl)
for 20 minutes. Extraction of the pigment was performed by adding 2 ml of 100%
methanol and incubating at 45οC for 30 minutes. Cultures were centrifuged and the
intensity of released pigment in the supernatants was measured by spectrophotometry at
460nm.

Autolysis Assay
Triton X-100-stimulated autolysis of bacterial cultures was measured as described
(Sieradzki and Tomasz, 1997). Primary cultures of LAC USA300 or LAC USA300 ∆agr
mutant (10 µl) were cultured in 5 ml TSB for 18 hr in the presence of absence of
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benzbromarone (5 µg/ml) or vehicle control. The cultures were then rapidly chilled in an
ice/ethanol bath, pelleted by centrifugation (3000 rpm, 4oC, 4 minutes) and washed once
with ice-cold distilled water. The bacteria were resuspended to an optical density of 1.0 at
620nm (OD620) in 50 mM glycine supplemented with Triton X-100 (0.01%) at pH 8.0.
Cultures were incubated at 37oC with shaking (200 rpm) and were removed at selected
timepoints, sonicated, and autolysis measured as the decrease in OD620.

Acid Killing Assay
Benzbromarone: Early exponential phase LAC USA300 or LAC300 ∆agr mutant (1 x
109) was incubated at 37oC with shaking (200 rpm) in PBS for 1.5 hr in the presence of
absence of benzbromarone (5 µg/ml). After the incubation, the cultures were centrifuged
(3000 rpm, 4oC, 4 minutes), resuspended in PBS acidifed with HCl to pH 2.5, and
incubated for an additional 2 hr. Serial dilutions of the bacteria were plated on sheep
blood agar plates to determine the surviving colony forming units.
Savirin: Early exponential phase LAC USA300 or LAC USA300 ∆agr mutant (1 x
108/ml in phenol red-free Dulbecco’s Modified Eagle Media, DMEM, containing 4.5g/L
D-glucose/2%Hepes) were incubated for 5 hr at 37oC with shaking (200 rpm) with 50 nM
synthetic AIP1 (used only with LAC USA300) in the presence or absence of savirin (5
µg/ml) or vehicle control. Bacteria were centrifuged (3000 rpm, 4oC, 4 minutes), washed
once with PBS, resuspended in DMEM/2%Hepes acidified with HCl to pH 2.5, and
incubated for an additional 1 hr. Dilutions were plated on sheep blood agar and viability
determined by enumerating colony forming units.

43

Oxidant Susceptibility Assay
Susceptibility of the bacteria to oxidants was measured as described (Liu et al., 2005).
Benzbromarone: LAC USA300 was cultured for 30 hr in the presence or absence of
benzbromarone (5 µg/ml). Bacteria were centrifuged (3000 rpm, 4oC, 4 minutes), washed
twice with PBS, and resuspended in PBS to an OD600 of 0.6. Hydrogen peroxide (H2O2)
(30% solution) was added to a 1.5% or 3.0% final concentration and the cultures were
incubated at 37oC with shaking (200 rpm) for 2 hr. Catalase (from bovine liver) (1,000
U/ml) was added to the cultures to quench the residual H2O2. Dilutions were plated on
sheep blood agar to determine surviving bacteria of each sample.
Savirin: Early exponential phase LAC USA300 or LAC USA300 ∆agr mutant (1 x
108/ml DMEM/2%Hepes) were incubated for 5 hr with 50 nM synthetic AIP1 (used only
with LAC USA300) in the presence or absence of savirin (5 µg/ml) or vehicle control.
Bacteria were centrifuged (3000rpm, 4oC, 4 minutes), washed once with PBS, and
resuspended in DMEM/2%Hepes. Hydrogen peroxide (H2O2) was added to a 1.5% final
concentration and the cultures were incubated at 37oC with shaking (200 rpm) for 2 hr.
Catalase (1,000 U/ml) was added to quench the residual H2O2. Dilutions were plated on
blood agar to determine bacterial survival.

Linoleic Killing Assay
Early exponential phase LAC USA300 were incubated at 37oC with shaking overnight
(18 hr) in TSB in the presence or absence of benzbromarone (5 µg/ml). The cultures were
centrifuged, washed twice with PBS, and the cultures were resuspended in TSB to an
OD600 of 0.3. The cultures were aliquoted to a volume of 1ml in 3ml polystyrene tube and
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linoleic acid (Sigma-Aldrich) was added to the cultures at various final concentrations
from 0.2 mM to 1.0 mM making duplicates of each concentration. Cultures with linoleic
acid were incubated as described above for 18 hr after which they were sonicated and
dilutions of the cultures were plated out on blood agar plates to determine bacterial
survival by enumerating CFUs.

Whole Blood Killing Assay
Early exponential phase LAC USA300 (1 x 108/ml DMEM/2%Hepes) were incubated for
5 hr with 50 nM synthetic AIP1 in the presence or absence of savirin (5 µg/ml) or vehicle
control. Bacteria were centrifuged (3000rpm, 4oC, 4 minutes), washed once with PBS,
and resuspended in DMEM. Bacteria were diluted (1 x 105/ml DMEM) and incubated in
10% normal human serum for 30 minutes at 37oC. After a brief sonication, 50 µl of
bacteria were mixed with 450 µl of heparinized whole mouse blood in 1.5 ml eppendorf
tubes and rotated end-over-end at 37oC for 2 hr. 100 µl of the solution was mixed with
100 µl PBS/1% Triton, sonicated, and plated on blood agar plates to determine bacterial
survival by enumerating CFUs (Data not shown).

Membrane Integrity Assay
Membrane integrity was measured as described using propidium iodide (Attia et al.,
2010). Primary cultures of LAC USA300 were cultured overnight (18 hr) in Roswell Park
Memorial Institute (RPMI) medium supplemented with 1% casamino acids (CAS) in the
presence or absence of savirin (5 µg/ml). The cultures were then pelleted, washed once
with PBS, and then resuspended in PBS supplemented with 1% bovine serum albumin
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(BSA). The samples were then set to an OD600 of 0.4 and then a select portion of the
samples were heat killed (90oC for 10 minutes) to serve as positive control. Aliquots of
50 µl of the samples were mixed with 1ml PBS/1% BSA containing 2 µg of propidium
iodide. Membrane damage was determined by measuring mean channelﬂuorescence
(MCF) using flow cytometry (Accuri C6)

Membrane Potential Assay
Membrane potential was measured as described (Gentry et al., 2010; Hu et al., 2010;
Novo et al., 1999). LAC USA300 was cultured overnight (18 hr) in TSB in the presence
or absence of savirin (5 µg/ml). The cultures were pelleted and washed twice with PBS.
The cultures were resuspended in PBS, set to an OD600 of 1.5, and a selection of the
samples of LAC bacteria alone were heat killed (90oC for 10 minutes) to serve as positive
control. 3,3′-dipropylthiacarbocyanine iodide (DiOC2(3)) was added to 500 µl samples of
the bacteria to a final concentration of 50 µM and samples were incubated at room
temperature in the dark for 5 minutes. 100 µl of each sample containing DiOC2(3) was
diluted into 600 µl of a reaction buffer consisting of 60 mM Na2HPO4, 60 mM NaH2PO4,
130 mM NaCl, 5mM KCl, 0.5 mM MgCl2, and 10 mM glucose. Flow cytometry was then
used to measure membrane potential (Accuri, C6). Measurements from both the red and
green channel were taken and data were presented as a ratio of red channel measurements
divided by the green channel measurements to reflect the shift to greater change in
membrane potential.
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Fibrinogen-Mediated Bacterial Promoter Activation Assay
Early exponential phase bacteria (2 x 107/ml TSB) containing plasmid agrP3 driving GFP
expression were incubated in polystyrene tubes with or without fibrinogen (American
Diagnostica, Inc.) (100 µg/ml), in the presence or absence of savirin (5 µg/ml) or vehicle
control. Cultures were incubated at 37oC with shaking (200 rpm) for 4 hr. After
incubation, bacteria were centrifuged (3000rpm, 4oC, 4 minutes), decanted, washed with
(PBS) with 0.1% Triton X-100, fixed with 1% paraformaldehyde containing 25 mM
CaCl2, sonicated, and then evaluated for GFP expression by flow cytometry (Accuri C6)
measured as the mean channel ﬂuorescence (MCF).

In Vitro Development of Resistance
Early exponential phase LAC USA300 (1 x 106/ml) were incubated for 10 days in 5 ml
TSB with or without the addition of clindamycin (Sigma) (0.1µg/ml) or savirin (5 µg/ml)
at 37oC with shaking (200 rpm). The bacteria were centrifuged, decanted, and
resuspended in 5 ml fresh TSB and new addition of drug was added to the respective
tubes every 24 hr. On the tenth day, samples were centrifuged, washed once with PBS,
and then plated onto sheep blood agar to determine the titer. The bacteria that had been
repeatedly exposed for 10 days and unexposed bacteria (starting concentrations of 1 x 106
in 5ml TSB) were then challenged in an overnight (18 hr) incubation with clindamycin
(0.1µg/ml) or savirin (5µg/ml). After 18 hr, the bacteria were plated to determine
viability. Bacteria repeatedly exposed to savirin for 10 days and unexposed bacteria (2 x
107/ml TSB) were incubated in 1ml cultures with 50 nM synthetic AIP1 in the presence
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or absence of savirin (5 µg/ml) for 2 hr at 37oC with shaking (200 rpm). Expression of
RNAIII was determined by qRT-PCR as described above.

Mice
The appropriate institutional committees approved all experiments involving animals.
SKH1-E mice ≈
( 8 -10 wk, ≈ 24 -32 g, male) were obtained from Charles River Labs
(Wilmington, MA).

Dermonecrotic Infection Model
Benzbromarone was solubilized in 12mM 2-hydroxypropyl β-cyclodextrin in endotoxinfree water. Savirin was solubilized in 0.5% hydroxypropyl methylcellulose in endotoxinfree water and 1M NaOH was added to a final concentration of 15mM. Sonication and
incubation in a 37oC water bath were necessary to ensure savirin was in solution.
Solutions were filtered with a 0.22µM filter (Millex-GV) before injecting. Early
exponential phase bacteria (4 x 107) were injected simultaneously with either
benzbromarone (5 µg), savirin (5 µg), or vehicle subcutaneously into the flank of SKH1E mice as described (Wang et al., 2007) using a 3/10cc insulin syringe with a 28 ½ gauge
needle (Becton Dickinson). Abscess area (white, puffy area) and ulcer area (necrotic
area) were recorded daily in addition to weight loss as evidence of illness. The abscess
area (mm2) is calculated from the equation:
{(π/6)[(length of the ulcer) x (width of the ulcer)]}
The ulcer area (mm2) is calculated from the equation:
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{(length of the ulcer) x (width of the ulcer)}
On Day 3 or Day 7, the mice were sacrificed using isoflurane inhalation. The
abscess/ulcer area was excised (1.5 cm2) and the spleens were removed. Tissues and
spleens were removed and placed in 1 ml of HBSS/HSA in a bead-beating tube
containing sterile 2.3 mm beads (Biospec, Bartlesville, OK) and stored on ice. Tissue and
spleen samples were processed for bacterial CFU by homogenizing the spleens in a bead
beater, diluting all samples 1:10 in 1 ml 1X PBS/0.1%Triton, sonicating the sample, then
plating serial dilutions on blood agar, as described (Rothfork et al., 2004).

In Vivo Development of Resistance
Early exponential phase bacteria (4 x 107/ml) were injected simultaneously with
clindamycin (0.1µg/ml) or savirin (1 µg/ml) into the flank of SKH1-E mice as described
(Wang et al., 2007) using a 3/10cc insulin syringe with a 28 ½ gauge needle (Becton
Dickinson). At 24hr, weight loss was recorded and the mice were sacrificed using
isoflurane inhalation. The abscess area was measured and spleens were removed and
placed in 1 ml of HBSS/HSA in a bead-beating tube and processed as described above.
Serial dilutions of the bacteria from the spleen were plated on blood agar plates and were
incubated at 37oC for 24 hr. Colonies were lifted from the blood agar plates and sonicated
in saline until a desired density (as measured by OD600 on the spectrophotometer) was
reached. These bacteria were injected simultaneously with clindamycin (0.1µg/ml) or
savirin (1µg/ml) into the flank of SKH1-E mice as before. At 24 hr, the mice were
sacrificed and the spleens were processed as described and plated. The procedure was
repeated twice more, carrying the bacteria taken from the spleen through four mice total
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for each treatment. After the fourth mouse in each treatment group was sacrificed, the
splenic bacteria taken from the plate were concentrated and stored in TSB/10% glycerol
at -80oC. The repeatedly exposed bacteria (from spleen) and unexposed bacteria were
diluted to a starting concentration of 1 x 106/ml in 5 ml TSB and challenged in an
overnight (18 hr) incubation in the presence of clindamycin (0.1µg/ml) or savirin
(1µg/ml). After 18 hr, bacteria were plated to determine viability. qRT-PCR assay was
also performed using unexposed bacteria or bacteria repeatedly exposed to savirin (from
spleen). 1ml cultures were incubated at a concentration of 2 x 107/ml in TSB with 50 nM
synthetic AIP1 in the presence or absence of savirin (1 µg/ml). Expression of RNAIII
determined by qRT-PCR as described previously after 1 hr incubation.

Statistical Evaluation
Data are displayed as the mean ± SEM. In vitro data were analyzed by the Student’s t test
using GraphPad Prism 4.0 and the in vivo data were analyzed by the Mann-Whitney U
test for non-parametrics using Statview for MacIntosh.
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CHAPTER 3
SAVIRIN, A SMALL MOLECULE INHIBITOR, TARGETS
STAPHYLOCOCCUS AUREUS VIRULENCE IN VITRO AND IN VIVO
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Introduction
Methicillin resistant Staphylococcus aureus (MRSA) has emerged as a major
public health threat (Chambers and Deleo, 2009; Klevens et al., 2007) and the worldwide
expansion of a single clone (USA300), associated with life threatening infections even in
immunocompetent adults (Lowy, 2007), has re-focused interest in developing novel
therapeutics to treat this infection (Garcia-Lara et al., 2005a). One strategy evolving to
treat antibiotic resistant infections is to develop drugs that target virulence but not
bacterial growth (Cegelski et al., 2008; Clatworthy et al., 2007; Rasko and Sperandio,
2010). This approach is postulated to limit the development of resistance while enhancing
host defense by permitting immune effectors to kill and clear the pathogenic bacteria
rendered avirulent by the drug. While this approach has had success in animal models of
primarily Gram-negative bacterial infection (Cegelski et al., 2008; Clatworthy et al.,
2007; Rasko and Sperandio, 2010), it has not been pursued for treatment of MRSA
infection. The virulence factors identified to date as essential for MRSA infection,
particularly those that contribute to the dermonecrotic skin infections typical of this
pathogen, are globally regulated in part by a quorum sensing operon, agr (Li et al., 2009;
Novick and Geisinger, 2008; Wang et al., 2007). Importantly, recent work from our
laboratory identifying apolipoprotein B as an innate barrier that antagonizes agr signaling
demonstrates that host defense against invasive infection can be accomplished by
blocking agr signaling (Peterson et al., 2008). Therefore, we hypothesized that small
molecule inhibitors (SMIs) identified by screening chemical libraries for antagonism of
agr signaling could ameliorate experimental agr-dependent MRSA infections.
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In this work, we describe a chemical compound identified in a high throughput
screen that we have termed savirin, for Staphylococcus aureus virulence inhibitor.
Savirin inhibited agr signaling in multiple S. aureus strains at a concentration that did not
affect bacterial growth. Its inhibition of agr signaling and the ultimate production of
virulence factors were verified by transcriptional analysis and assays for virulence factor
function. It prevented the development of dermonecrotic ulcers following infection with
agr+ bacteria in an experimental mouse model of skin and soft tissue infection.
Moreover, repeated exposure of S. aureus to savirin either in vivo or in vitro did not
induce resistance in those bacteria to the inhibition of agr signaling by savirin. These data
demonstrate that chemical compounds can be identified that target quorum sensing
dependent S. aureus virulence without inducing significant resistance upon repeated
exposure and thus have promise as potential therapeutic adjuncts for the treatment of
infections caused by this pathogen.

Results
Savirin inhibits agr signaling without affecting bacterial viability
The agr operon is activated by an autoinducing pheromone peptide (AIP) that
binds to its cognate receptor and leads to activation of a promoter (agr:: P3) that produces
a regulatory RNA, RNAIII, that is the effector of the operon. RNAIII alters the
transcriptional profile of the bacteria to upregulate production of secreted virulence
factors like capsule, toxins, and tissue damaging enzymes while downregulating surface
adhesins (Novick et al., 1993).
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A screen was performed by the New Mexico Molecular Libraries Screening
Center targeting AIP-dependent bacterial quorum sensing utilizing the HyperCyt high
throughput flow cytometry platform. The HyperCyt system interfaces a flow cytometer
and autosampler (Edwards et al., 2004). Samples are sequentially aspirated from the
wells of a 384-well microplate separated by a bubble of air. This delivery of samples to
the flow cytometer makes the HyperCyt system 30 times faster than commercial
alternatives (Edwards et al., 2004). A total of 24,087 compounds from the Molecular
Libraries Small Molecule Repository (MLSMR) were screened to identify novel small
molecule inhibitors of the quorum sensing pathway, specifically identification of a small
molecule that inhibits the binding of AIP to cellular receptors.
A high-throughput fluorescence-based screening assay was used which examined
the ability of the tested compounds to inhibit the activation of the RNAIII promoter
encoded with a plasmid which drives GFP expression (Sawires and Gresham, 2008).
When these reporter bacteria are in early exponential phase before quorum sensing has
begun, they are non-fluorescent. When incubated with exogenous synthetic AIP1, the
bacteria undergo quorum sensing and the RNAIII promoter is activated thus activating
GFP production. In the same timeframe (3 hr), reporter bacteria incubated without
exogenous synthetic AIP addition did not produce enough endogenous AIP to undergo
quorum sensing so therefore these bacteria remained non-fluorescent. The test
compounds were added at a final concentration of 2 µM and were measured by their
ability to inhibit GFP fluorescence (RNAIII activation) in the presence of 0.1 µM AIP1
and a bacterial concentration of 2 x 107.
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Savirin was one of ten compounds identified in a screen of over 24,000
compounds for inhibition of agr::P3 promoter activation by the Molecular Libraries
Screening Centers Network (MLSCN) (University of New Mexico). Savirin (3-(4propan-2-ylphenyl) sulfonyl-1H-triazolo [1,5-a] quinazolin-5-one (CID# 3243271)
(Figure 1A) inhibited agr::P3 promoter activation with an IC50 of < 1.0 µM. To be a
useful therapeutic, ideally savirin would inhibit agr signaling without inhibiting bacterial
growth. To determine if savirin affected either short term or long term growth, we
cultured a USA300 strain, LAC, in trypticase soy broth (TSB) in the presence or absence
of savirin (5 µg/ml) refreshing the broth and the drug every 24 hr. Viability was tested
every 24 hr by enumerating viable colony forming units (CFU). Over the course of 72 hr,
incubation in the presence of savirin had no effect on the viability of the bacteria as
compared to bacteria grown in broth (Figure 1B).
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Figure 1. Savirin does not affect bacterial viability in the LAC USA300 strain
A) Chemical Structure of savirin (CID# 3243271) 1 of 10 compounds identified with an
IC50<1 µM for the inhibition of agr:: P3 promoter activation in a MLSCN screen of over
24,000 compounds
B) LAC USA300 WT was incubated in TSB in the presence or absence of savirin (5
µg/ml) and growth was determined every 24hr by enumerating colony forming units.
Arrows indicate timing of savirin and fresh broth addition. Data are represented as the
Mean ± SEM, n=3
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All S. aureus strains can be classified into one of four groups based on the
sequence of the AIP produced and its cognate receptor, AgrC. While the majority of
clinical isolates are agr type 1, all types contribute to human disease. PFGE type strains
USA300 and USA400, the most clinically problematic and abundant community acquired
MRSA strains are agr type 1 and agr type 3 respectively (Lowy, 2007). For savirin to be
a useful therapeutic against S. aureus infections, including those caused by antibiotic
resistant strains, it should have actions against multiple, if not all, agr backgrounds.

To determine if savirin could be used to inhibit agr::P3 promoter activation in
multiple genetic backgrounds, we used reporter strains of each agr type where activation
of the agr P3 promoter drives expression of GFP (agr1: AH1677/LAC USA300, agr2:
AH430/502A, agr3: AH1747/MW2, and agr4: AH1872/MNTG). The bacteria were
incubated for 18 hr without addition of exogenous AIP, in the presence or absence of
savirin (5 µg/ml) or an equal volume of vehicle control prior to evaluation of GFP
expression by flow cytometry. Savirin significantly inhibited agr activation in the agr1
strain LAC (Figure 2A), indicating that savirin can antagonize AIP1 signaling without
affecting bacterial growth (CFU) (Figure 1B). In addition, savirin inhibited agr::P3
activation in other agr backgrounds; agr type 2 strain 502A (Figure 2B), agr type 3 strain
MW2 (Figure 2C), and agr type 4 strain MNTG (Figure 2D). These data demonstrate that
the small molecule savirin significantly inhibits agr signaling of all four agr types at a
concentration that does not inhibit bacterial growth in vitro.
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Figure 2. Savirin inhibits agr signaling in multiple strain types
agr::P3 promoter activation is inhibited in
(A) S. aureus agr1 strain (AH1677/LAC with agr:: P3-gfp, 2×107/ml)
(B) S. aureus agr2 strain (AH430/502A with agr:: P3-gfp, 2×107/ml)
(C) S. aureus agr3 strain (AH1747/MW2 with agr:: P3-gfp, 2×107/ml)
(D) S. aureus agr4 strain (AH1872/MNTG with agr:: P3-gfp, 2×107/ml)
during 18 hr of culture in the presence or absence savirin or equal volume of vehicle
control. Reporter assay was performed in a microtiter plate assay in a final volume of 50
µl containing ~4 x 107 bacteria and 5 µg savirin. Data are represented as the mean
channel fluorescence (MCF) of total S. aureus by flow cytometry, ± SEM; ***p<0.0005,
n=5
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The agr regulated virulence transcriptome is significantly affected by savirin
Microarray analysis can provide valuable information as to the global
transcriptional effects of savirin on LAC USA300 and its ∆agr mutant. A microarray
analysis was performed in collaboration with Dr. Frank DeLeo at the Rocky Mountain
Labs, NIAID, NIH. cDNA of bacteria incubated with exogenous AIP for 5 hr was
hybridized to a custom Affymetrix GeneChip which contained 100% of the USA300
LAC genome. Three comparisons were performed in which the alterations of open
reading frames were examined; LAC vs LAC+savirin, ∆agr vs ∆agr+savirin, and LAC
vs ∆agr. Figure 3A depicts a diagram of the effects of savirin on LAC USA300 and its
∆agr mutant. Savirin affected 211 open reading frames in the wild type strain
representing 7.6% of the total LAC genome, up-regulating 59 and down-regulating 152.
In the ∆agr mutant, 52 open reading frames were affected by savirin representing 1.8% of
the total genome, 17 up-regulated and 35 down-regulated. Savirin affected 46 open
reading frames similarly between the wild type and mutant, with 19 of those being upregulated and 27 down-regulated. These data indicate that savirin primarily alters
transcription in the agr+ strain while minimally altering transcription in the ∆agr mutant.
An analysis of the actual genes altered revealed that 94 open reading frames significantly
down-regulated by savirin in the agr+ strain (LAC vs LAC+savirin) were also down
regulated in the absence of agr (LAC vs ∆agr), including all of the major virulence
factors regulated by agr. These include genes for capsule production, multiple proteases,
lipases, hemolysins, and cytolytic peptides (Table 1). In addition, genes involved in
resistance to acid-mediated stress (potassium transporter and urease) were also down-
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regulated by savirin (Table 1). Consistent with our observations made above (Figure 2),
these data indicate that savirin has a significant inhibitory effect on agr-regulated gene
transcription.
Of the genes affected in both the wild type and the ∆agr mutant, a subset includes
genes encoding multidrug efflux pumps including the MATE efflux pump (increased
3.71 fold in wild type and 2.77 fold in the ∆agr mutant) and the less well understood
multidrug resistance protein A (increased 10.84 fold in wild type and 8.45 in the ∆agr
mutant) while transcription of the genes for the better understood drug transporters NorA
and QacA were not affected, indicating that some stress response common to both strains
is activated by savirin. The open reading frame most dramatically up-regulated in both
strains by savirin is a hypothetical protein (increased 30.75 fold in wild type and 30.51
fold in the ∆agr mutant) suggesting that savirin may alter poorly understood stress
responses.
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Figure 3. Microarray analysis of the impact of savirin on gene transcription of agr+
and ∆agr CA-MRSA
Effect of savirin on the transcriptome of LAC USA300 and its ∆agr mutant. Bacteria
were cultured in the presence of exogenous AIP1 (50 nM) in the presence or absence of
savirin (5 µg/ml). RNA was extracted, purified, reverse transcribed to cDNA, and
hybridized to the Affymetrix GeneChip RML7a520611F containing the USA300
genome. n=3, significant effect > 2 fold change, p<0.05
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Table 1. agr-regulated genes altered by savirin in LAC agr+
Gene name, gene function, and fold change of gene altered by savirin in LAC agr+
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Savirin inhibits RNAIII synthesis and subsequent virulence factor production in
multiple genetic backgrounds
RNAIII synthesized downstream of agr::P3 activation is responsible for the
transcriptional control of the production of numerous virulence factors including the
cytolytic peptide psm α and the cytotoxin alpha hemolysin. Both of these are integral in
causing the tissue destruction seen in skin and soft tissue infections caused by CA-MRSA
strains (Li et al., 2009). Based on the results showing the ability of savirin to inhibit the
agr P3 promoter and the results of our microarray analysis showing down-regulation of
agr-dependent virulence factor gene expression, we predicted that savirin would be able
to inhibit the synthesis of RNAIII in addition to the transcription of subsequent virulence
factors that lie downstream of RNAIII.
To address this, we selected the agr type 1 USA300 strain LAC and utilized qRTPCR to measure RNAIII expression either following stimulation by addition of
exogenous synthetic AIP1 or during culture relying on endogenous production of AIP by
the bacteria. Early exponential phase USA300 LAC were grown for 2 hr (with exogenous
AIP1) or 5 hr (endogenous production of AIP1) at 37oC in the presence or absence of
savirin or vehicle control. As shown in Figure 4A, RNAIII production was significantly
inhibited by the addition of savirin as compared to the vehicle control. Figure 4B shows a
similar effect in the 5 hr assay where the AIP production was produced endogenously
during culture. Savirin was also able to significantly inhibit the expression of RNAIII
when added after the initiation of the bacterial culture (Figure 4C). Early exponential
phase LAC were grown for 3 hr at 37oC after which time savirin, vehicle, or broth were
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added to the cultures and then incubated for an additional 2 hr. As Figure 4C shows, even
when added to the cultures after 3 hr of incubation, savirin was still able to significantly
inhibit the production of RNAIII transcripts.
Host microenvironments that mediate bacterial clumping can enhance densitydependent virulence gene expression and this includes the clumping of this pathogen by
the coagulation protein fibrinogen that creates constrained microenvironments around the
bacteria (Rothfork et al., 2003a). To determine if savirin would inhibit agr::P3 promoter
activation in an environment likely to be encountered in vivo, we included fibrinogen to
promote clumping and quorum sensing. Figure 4D shows that even in the presence of
fibrinogen, which mediates activation in the samples of bacteria alone or bacteria with
vehicle, savirin is still able to significantly inhibit the activation of the promoter.

The virulence factors produced downstream of RNAIII are largely responsible for
the pathogenesis of the disease. Because savirin inhibited expression of RNAIII, we
predicted that the production of virulence factors controlled by RNAIII would be
similarly impeded. We examined the effect of savirin on gene expression for alpha
hemolysin. Early exponential phase LAC was grown for 5 hr (with exogenous AIP) or 8
hr (endogenous production) at 37oC in the presence or absence of savirin. The addition of
savirin to the culture significantly inhibited the production of alpha hemolysin mRNA
both in assays where exogenous AIP was added (Figure 5A) and where the bacteria were
allowed to spontaneously produce their own AIP (Figure 5B). qRT-PCR was used to
determine the capacity of savirin to inhibit the expression of psmα mRNA which is a
direct readout of AgrA activation (Queck et al., 2008). As expected, savirin inhibited
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psmα mRNA in a 2 hr assay where exogenous AIP was added (Figure 5C). To confirm
that savirin inhibited toxin production, we measured the function of alpha hemolysin by
its ability to lyse rabbit erythrocyes. As shown in Figure 5D, LAC produced an abundant
amount of alpha hemolysin toxin when cultured for 18 hr which was completely
abrogated by the addition of savirin. These data demonstrate that savirin can inhibit the
production of multiple AIP1 dependent virulence factors in vitro, both at the transcript
and at the protein level, and confirms the results we obtained in the microarray analysis.
We show that inhibition of quorum sensing by savirin can inhibit the phenotypic switch
that prevents RNAIII expression and the downstream up-regulation of the virulence
factors described above.
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Figure 4. Savirin antagonizes agr1 and RNAIII expression
A) LAC USA300 (2 x 107/ml TSB) was incubated with 50 nM synthetic AIP1 in the
presence or absence of savirin (5 µg/ml). RNA was extracted, purified, reverse
transcribed to cDNA, and then gene expression relative to endogenous control 16s was
determined using a probe for RNAIII after 1 hr of culture. ***p<0.0005, n=4
B) LAC USA300 (2 x 107/ml TSB) was incubated without synthetic AIP1 in the presence
or absence of savirin (5 µg/ml). Expression of RNAIII determined by qRT-PCR as
described above after 5 hr. ***p<0.0005, **p=0.0015, n=4
C) Effect of savirin (5 µg/ml) added to a culture of LAC USA300 (2 x 107/ml TSB) at 3
hr and then incubated for an additional 2 hr. Expression of RNAIII determined by qRTPCR as described above. **p=0.0012 n=3 Data are represented as mean ± SEM
D) LAC USA300 (2 x 107/ml TSB) was incubated with fibrinogen (100 µg/ml) for 4 hr in
the presence or absence of savirin (5 µg/ml). Data are represented as the mean channel
fluorescence (MCF) of total S. aureus by flow cytometry, and as the mean ± SEM;
***p<0.0005, n=3
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Figure 5. Savirin antagonizes agr1 and virulence factor production
A) LAC USA300 (2 x 107/ml TSB) was incubated with 50 nM synthetic AIP1 in the
presence or absence of savirin (5 µg/ml). RNA was extracted, purified, reverse
transcribed to cDNA, and then gene expression relative to endogenous control 16s was
determined using a probe for hla after 5 hr of culture. ***p<0.0005, n=4
B) LAC USA300 (2 x 107/ml TSB) was incubated without synthetic AIP1 in the presence
or absence of savirin (5 µg/ml). Expression of hla determined by qRT-PCR as described
above after 8 hr. ***p<0.0005, **p=0.0015, n=4
C) LAC USA300 (2 x 107/ml TSB) was incubated with 50 nM synthetic AIP1 in the
presence or absence of savirin (5 µg/ml). Expression of PSMα determined by qRT-PCR
as described above after 1 hr. *p=0.0164 n=3 Data are represented as mean ± SEM
F) Effect of savirin (5 µg/ml) added to an overnight culture of LAC in which alphahemolysin in the supernatant was measured by lysis of rabbit erythrocytes.
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Although USA300 is responsible for the majority of MRSA infections, the other
agr backgrounds also cause disease, most notably agr type 3 USA400. Therefore, it was
important clinically to determine whether savirin would inhibit virulence factor
production in strains other that agr1 type strains. Based on the observation that savirin
inhibited agr signaling in multiple agr backgrounds (Figure 2), we hypothesized that the
drug would have a similar inhibitory effect on the production of virulence factors of agr2
strains and agr3 strains. We examined alpha hemolysin production in an agr2 strain
(502A) and an agr3 strain (1560). Both 502A and 1560 were cultured for 18 hr in the
presence of absence of savirin and alpha hemolysin was measured by the supernatants
ability to lyse rabbit erythrocytes. As predicted, Figure 6A and 6B show that savirin
inhibited the production of alpha hemolysin in 502A and 1560 respectively. Next qRTPCR was used to determine the effect of savirin on the production of psmα. As expected,
savirin inhibited psmα expression in a 2 hr assay where exogenous AIP was added in
both 502A and MW2 (Figure 6C, 6D). These data demonstrate that savirin can inhibit the
production of virulence factors in agr2 and agr3 strains in vitro.
To confirm that savirin could inhibit alpha hemolysin production by current
clinical isolates, we obtained clinical isolates from patients at the New Mexico VA
Health Care System. A selection of these strains (both MRSA and MSSA) that produced
a measurable amount of alpha hemolysin was incubated for 18 hr in the presence or
absence of savirin. Figure 6E shows that regardless of infection location or methicillin
susceptibility, savirin was able to inhibit alpha hemolysin production in all clinical
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isolates tested. These data suggest that savirin is a small molecule inhibitor that
selectively targets virulence in all agr strains as well as clinical isolates.
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Figure 6. Savirin Antagonizes agr2 and agr3 Signaling and Virulence Factor
Production
A.B) Effect of savirin (5 µg/ml) added to an overnight culture of agr 2 strain 502A (B) or
agr 3 strain MW2 (B) in which alpha-hemolysin in the supernatant was measured by lysis
of rabbit erythrocytes.
C.D) Gene expression of PSMα as measured by qRT-PCR as a percentage of AIP
(100%) in agr 2 strain 502A (C) or agr 3 strain MW2 (D) (2 × 107/ml) incubated with 50
nM synthetic AIP2 or AIP3 in the presence or absence of savirin (5 µg/ml) incubated at
37oC with shaking for 2 hours. n=2, n=3 respectively Data are represented as mean ±
SEM
(E) Effect of savirin (100 µg/ml) added to overnight cultures of various clinical isolates
in which alpha-hemolysin in the supernatant was measured. The upper row is treated with
vehicle control and the lower row contains savirin.
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Savirin exhibits protection in an agr-dependent dermonecrotic S. aureus infection
Skin and soft-tissue infections predominate as the most frequent form of disease
caused by CA-MRSA and these vary in severity from impetigo, a painless rash, to lifethreatening necrotizing fasciitis. Abscesses are the most common presentations, affecting
50% to 75% of patients that present with CA-MRSA (Stryjewski and Chambers, 2008).
Both PSMα and alpha hemolysin are integral factors in causing the tissue destruction that
constitute skin and soft tissue infections (Li et al., 2009). Because savirin inhibited the
production of these toxins in vitro, we predicted that savirin would inhibit production of
in vivo as well and be protective in a dermonecrotic mouse model of infection.
To test whether treatment with savirin could confer protection in an invasive S.
aureus infection, we used a mouse model of dermonecrosis (Wang et al., 2007). Early
exponential phase LAC agr+ bacteria were injected subcutaneously into the flank of
SKH1-E hairless mice with the addition of either savirin or vehicle alone. The infections
were monitored for three days and abscess area, ulcer area, and weight loss were
recorded. At the termination of the experiment, the ulcerated areas were excised (1.5 cm2)
and homogenized to determine the number of bacteria. As shown in Figure 7A-7C,
infection of the mice with LAC in the presence for savirin resulted in smaller abscesses
and ulcer area as compared to those given vehicle. Mice given savirin also experienced
decreased weight loss compared to the mice treated with vehicle (Figure 7D), while the
number of viable bacteria in the ulcerated tissue indicate that savirin can have a
therapeutic effect in a dermonecrotic infection and protects without altering the viability
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of the bacteria at the 3 day time point. This suggests that the drug is not killing or
restricting growth of the bacteria but rather affecting what the bacteria are producing.
CA-MRSA skin infections are transmitted from person to person with
interfamilial outbreaks being reported (Ippolito et al., 2010). CA-MRSA infections are
also associated with increased expense and duration of hospital stays so resolution time
of the infection is an important factor to take into consideration. Because savirin
exhibited protection in an in vivo dermonecrosis model, we predicted this initial
protection would lead to faster resolution of the ulcer and enhanced clearance of the
bacteria by the host immune system. Figure 8A shows the decreased necrotic area of the
savirin-treated mice on Day 7 in contrast to the significantly larger necrotic area of the
mice treated only with vehicle. Figure 8B and 8C show the course of the infection over
the seven days measuring ulcer area (Figure 8B) and abscess area (Figure 8C) with the
peak of the infection area at Day 3 and then subsequent resolution. After seven days post
infection, the mice treated with savirin had a lower bacterial burden in the necrotic area
(Figure 8D) and in the spleen (Figure 8E). These data illustrate that bacteria treated with
savirin are cleared more readily than bacteria treated with vehicle thus leading to quicker
resolution of the infection.
Due to the overwhelming percentage of abscess manifestations that MRSA
patients present with, the in vivo model of dermonecrosis we utilize for these experiments
is clinically relevant. Our results showing that savirin is protective in an in vivo
dermonecrotic infection suggests that savirin may be a useful therapeutic against skin and
soft tissue infections caused by CA-MRSA.
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Figure 7. Effect of savirin on an invasive dermonecrotic S. aureus infection with
LAC USA300 over three days
A) LAC USA300 WT (5 x 107/ml saline at early exponential phase) were injected
subcutaneously on the flank (n=11 mice for each group, n=4 for saline) with either 5 µg
savirin or equal volume of vehicle. Pictures of the injection sites were taken at three days
B.C.D.E.F) Measurements of dermonecrosis (ulcer area (B) and abscess area (C)), weight
loss (D), CFUs from the lesion (n=5) (E), and CFUs from the spleen (n=5) (F) were taken
on Day 3 of the infection. Savirin compared to vehicle: **p=0.0027, *p<0.026. Data
represented as the mean ± SEM.
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Figure 8. Effect of savirin on the resolution of an invasive dermonecrotic S. aureus
infection with LAC USA300
A) LAC USA300 WT (5 x 107/ml saline at early exponential phase) were injected
subcutaneously on the flank (n=6 mice for each group) with either 5 µg savirin or equal
volume of vehicle. Pictures of the injection sites were taken at seven days
B.C.D.E) Measurements of dermonecrosis (ulcer area (B) and abscess area (C)), CFUs
from the lesion (p=0.16) (D), and CFUs from the spleen (p<0.05) (E) were taken on Day
7 of the infection. Data represented as the mean ± SEM
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S. aureus remains sensitive to inhibition of quorum sensing by savirin after
repeated exposure both in vitro and in vivo
When bacterial growth is targeted through the use of bacteriocidal or
bacteriostatic agents such as antibiotics, selective pressure is generated in which
mutations arise which can lead to drug resistance. In order for savirin to have therapeutic
potential, the bacteria must remain sensitive to the drug over repeated exposure. To
address whether bacterial sensitivity to savirin was retained through successive
exposures, we chose to repeatedly challenge the bacteria in vivo with the traditional
antibiotic clindamycin to serve as a positive control. We injected SKH1-E mice
subcutaneously on the flank with early exponential phase LAC USA300 and a subinhibitory dose of clindamycin. After 24 hr, the spleen was removed and bacteria cultured
from that spleen were combined with clindamycin and used to infect another mouse. This
procedure was carried through four mice with the final splenic bacteria being challenged
in an 18 hr growth assay side by side with unexposed bacteria. As shown in Figure 9A,
the growth inhibitory effects of clindamycin can be overcome by four passages through
mice. We used this procedure to then test whether the action of savirin on the bacteria can
be overcome by repeated exposure in vivo. We injected SKH1-E mice subcutaneously on
the flank with early exponential phase LAC USA300 and a sub-optimal dose of savirin
and followed the identical procedure. No change was seen in bacterial viability between
drug treated and control or between the unexposed and the repeatedly exposed bacteria
(Figure 9B). qRT-PCR was used to measure RNAIII expression to compare the
sensitivity to savirin between the unexposed bacteria and the bacteria repeatedly exposed
in vivo. Bacteria from the spleen of the fourth mouse were incubated for 2 hr in the
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presence or absence of savirin and the bacteria that had been repeatedly exposed to
savirin in vivo still retain sensitivity to RNAIII inhibition by the drug (Figure 9C). These
data suggest that within the time frame that S. aureus can develop resistance to the
growth inhibitory effects of clindamycin in vivo, they still retain sensitivity to the effects
of savirin.
We next determined whether that sensitivity to savirin was retained through
successive exposures in vitro in order to confirm our in vivo findings. We incubated LAC
USA300 for ten days in the presence of clindamycin, refreshing the broth and drug every
24 hr. The repeatedly exposed bacteria were challenged in an 18 hr viability assay side by
side with unexposed bacteria. As shown in Figure 10A, the growth inhibitory effect that
clindamycin has on unexposed bacteria could be almost abolished by ten days of repeated
exposure. We then followed a similar procedure, exposing bacteria to savirin for ten days,
refreshing the broth and drug every 24 hr. We first tested for effects on bacterial viability
and found no change in growth between drug treated and control or between the
unexposed and the repeatedly exposed bacteria (Figure 10B). We used qRT-PCR to
measure RNAIII expression to compare the sensitivity to savirin between the unexposed
bacteria and repeatedly exposed bacteria. Figure 10C shows that the repeatedly exposed
bacteria retained sensitivity to savirin for RNAIII inhibition equal to that of unexposed
bacteria. Our data demonstrate no induction of resistance at the time points used and that
the bacteria remain sensitive to the effects of savirin while during the same time frame
the bacteria did develop resistance to a currently prescribed and commonly utilized
antibiotic.
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Figure 9. Bacteria remain sensitive to inhibition of agr signaling by savirin after
repeated exposure in vivo
A.B) LAC USA300 (4 x 107/ml) was injected simultaneously with clindamycin (0.1µg)
(A) or savirin (1µg) (B). After 24 hr, mice were sacrificed and spleens were homogenized
and plated on blood agar. Colonies were lifted and injected simultaneously with
clindamycin (0.1µg) (A) or savirin (1µg) (B) into the flank of mice. Process was repeated
for a total of four mice in each treatment group. Repeatedly exposed bacteria (in vivo)
and unexposed bacteria were challenged in an 18 hr incubation with clindamycin
(0.1µg/ml) (A) or savirin (5 µg/ml) (B). Data are depicted as the mean +/- SEM of 3
replicates of two representative experiments. ***p<0.0001.
C) Unexposed bacteria or bacteria repeatedly exposed to savirin in vivo (2x107/ml TSB)
incubated with 50 nM synthetic AIP1 in the presence or absence of savirin (5µg/ml).
Expression of RNAIII determined by qRT-PCR as described previously after 1 hr. Data
are depicted as the mean +/- SEM. n=4-6. AIP1+vehicle compared to AIP1+savirin:
***p<0.0001.
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Figure 10. Bacteria remain sensitive to inhibition of agr signaling by savirin after
repeated exposure in vitro
A.B) LAC USA300 is incubated for 10 days in TSB with or without clindamycin (0.1
µg/ml (A) or savirin (5 µg/ml) (B) with repeated addition every 24 hr. Repeatedly
exposed bacteria and unexposed bacteria were challenged in an 18 hr incubation with
clindamycin (0.1 µg/ml) (A) or savirin (5 µg/ml) (B). Data are depicted as the mean +/SEM of 3 replicates of two representative experiments. ***p<0.0001.
C) Unexposed bacteria or bacteria repeatedly exposed to savirin (2 x 107/ml TSB)
incubated with 50 nM synthetic AIP1 in the presence or absence of savirin (5 µg/ml).
Expression of RNAIII determined by qRT-PCR as described previously after 1 hr. Data
are depicted as the mean +/- SEM. n=4. AIP1+vehicle compared to AIP1+savirin:
***p<0.0001.
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Savirin-induced alterations in agr-regulated genes predict enhanced innate
immune killing and potential membrane damage
The strategy behind inhibiting bacterial virulence through the use of savirin is to
attenuate the bacteria, ameliorate the infection, and allow the host immune effectors to
clear the pathogen. We postulated that to be an effective therapeutic, savirin treatment
would enhance bacterial killing by the host innate immune system. One such immune
effector is low pH that is integral in host defense. Acidic conditions are key to host
defense of the skin as well as the phagolysosome of macrophages that acidifies to destroy
engulfed bacteria. The microarray analysis demonstrated that some of the bacterial genes
down-regulated in response to savirin treatment were agr-dependent genes responsible
for the generation of ammonia, an essential component for bacterial survival in acidic
environments. This led us to predict that treatment with savirin would decrease bacterial
survival in acidic conditions. We used in vitro tests with acidic buffer to replicate the host
innate effector to determine if exposure to savirin made the bacteria more susceptible to
killing by acid. Specifically we cultured LAC USA300 or ∆agr in DMEM/2%Hepes for 5
hr in the presence of absence of savirin. After washing, the bacteria were incubated in
acidic conditions for 1 hr. As shown in Figure 11A, the wild type bacteria were
significantly more susceptible to killing by acid when they had been exposed to savirin
while the ∆agr strain (Figure 11B) showed no difference but had decreased survival in all
the groups tested. These data illustrate that exposure to savirin makes the LAC wild type
bacteria more susceptible to killing by acid, an innate effector.
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Figure 11. Exposure to savirin results in increased killing of the wild type bacteria
to acid
A.B) LAC USA300 (A) or LAC USA300 ∆agr mutant (B) (1x108/ml DMEM/Hepes)
incubated for 5hr with 50 nM synthetic AIP1 (used in LAC USA300 only) in the
presence or absence of savirin (5 µg/ml). Bacteria were washed and resuspended in
DMEM/Hepes, pH 2.5 for 1hr. Dilutions were plated on sheep blood agar and viability
determined by enumerating colony forming units. **p=0.004, n=6-12, Data represented
as the mean ± SEM.
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To determine if the inhibition of capsule production by savirin led to increased
killing by phagocytes, we performed a whole blood killing assay in which LAC USA300
were cultured in DMEM/2%Hepes for 5 hr in the presence of absence of savirin. After
washing and diluting, the bacteria were incubated with whole mouse blood for 2 hr.
Under the conditions of this assay, we failed to see any killing of either group of bacteria
and instead saw 1 log of growth after the 2 hr incubation (Data not shown).
The microarray analysis demonstrated that transcripts for membrane transport
proteins (eg; multidrug resistance transporter) were modestly up-regulated by exposure to
savirin in both agr+ and ∆agr. These increased transcript levels may be indicative of a
membrane stress response and can be induced following exposure to antibiotics. This led
us to postulate that savirin may be acting on the membrane of cell. To address this, we
first determined if savirin affected membrane potential which is a mechanism employed
by many antibiotics (Gentry et al., 2010; Hu et al., 2010; Novo et al., 1999). LAC
USA300 was incubated for 18 hr in the presence of absence of savirin, washed, and heatkilled LAC was used as a positive control. The bacteria were then loaded with DiOC2 a
fluorophore which exhibits green fluorescence in all bacterial cells but shifts toward red
emission as the dye molecules self-associate at higher cytosolic concentrations following
disruption of membrane potential. As Figure 12A shows, savirin-treated bacteria had no
increase in fluorescence indicating limited membrane disruption as compared to heat
killed LAC. These data suggest that the mechanism of action of savirin is unique from
these membrane disruption events.
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Antibiotics that create pores in the bacterial membrane can also induce a
membrane stress response that leads to reduced membrane integrity. We used propidium
iodide to detect membrane damage that may be caused by the addition of savirin. (Attia et
al., 2010). Specifically, we incubated LAC USA300 cultures for 18 hr in RPMI/1% CAS
in the presence or absence of savirin (5 µg/ml) and used heat-killed bacteria as a positive
control. Propidium iodide was added to each sample at a final concentration of 2 µg/ml.
Mean channel ﬂuorescence (MCF) was measured by flow cytometry as a readout of
membrane damage. Figure 12B shows that there is no increase in membrane damage
(MCF amount) upon treatment with savirin compared to heat killed bacteria. These data
suggest that savirin-induced alterations in membrane integrity are unlikely to contribute
to the effects of savirin on agr signaling.
If the savirin was inhibiting quorum sensing by blocking the secretion of AIP by
AgrB, we hypothesized that if we added excess exogenous AIP, this inhibition of RNAIII
gene expression could be overcome. To test this hypothesis, we added excess exogenous
AIP into the bacterial cultures in the presence or absence of savirin to determine if the
inhibition of RNAIII gene expression by the inhibitor could be overcome. As shown in
Figure 12C, even when 200 nM exogenous AIP was added, savirin was still able to
significantly inhibit RNAIII gene expression. These data suggest that since the effects of
savirin cannot be overcome with excess exogenous AIP, that savirin is not exerting its
primary effect on agr signaling by inhibiting AIP secretion by AgrB. On aggregate, our
data indicate that savirin does not inhibit agr signaling by inducing changes in membrane
potential or damaging membrane integrity.
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Figure 12. Effect of savirin on bacterial membrane charge and integrity
A) LAC USA300 was cultured 18 hr in TSB in the presence or absence of savirin (5
µg/ml). Bacteria were washed, resuspended in PBS, and equalized to OD600 of 1.5.
DiOC2 was added to samples at a final concentration of 50 µM, incubated in the dark for
5 minutes, then diluted 1:6 in reaction buffer described previously. Data are presented as
a ratio of the red channel value divided by the green channel value. n=4
B) LAC USA300 was cultured 18 hr in RPMI/1% CAS in the presence or absence of
savirin (5 µg/ml). Bacteria were washed, resuspended in PBS/1% BSA, and equalized to
OD600 of 0.4. 50 µl of the samples were mixed with 1ml PBS/1% BSA containing 2 µg of
propidium iodide. Data are represented as the mean channel ﬂuorescence (MCF) of total
S. aureus by by flow cytometry. n=4
C) LAC USA300 (2 x 107/ml TSB) was incubated with 50 nM, 100 nM, or 200 nM
synthetic AIP1 in the presence or absence of savirin (5 µg/ml). Expression of RNAIII
determined by qRT-PCR as described previously after 1 hr of culture. n=2
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Discussion
New therapies are required for treatment and prevention of invasive S. aureus
infections. A new therapeutic strategy is the development of drugs that target virulence
factor production but not growth. In this work, we demonstrate that the small molecule,
savirin, inhibits the production of agr-dependent virulence factors that render the bacteria
less virulent. This allows the host to clear the infection by immune effectors and limits
the likelihood of the bacteria developing resistance.
The data presented here directly address four criteria we had deemed essential for
a successful small molecule inhibitor of S. aureus quorum sensing-dependent virulence.
We show that savirin treatment inhibits agr signaling and subsequent downstream
virulence factor production in an agr1 strain without affecting bacterial viability. We also
show that savirin can inhibit agr signaling and virulence factor production in various agr
backgrounds and in numerous clinical isolates, indicating that savirin may have clinical
therapeutic relevance. Importantly, we demonstrate that multiple re-exposures of this
pathogen to the drug either in vivo or in vitro did not induce resistance of the bacteria to
subsequent savirin-mediated inhibition of agr signaling timepoints we investigated.
We illustrate that savirin inhibits S. aureus virulence in vivo. We show that mice
treated with savirin are significantly protected from the dermonecrotic ulcers resulting
from the production of the cytolytic proteins alpha hemolysin and PSM α in an infection
with a CA-MRSA USA300 strain. Despite significant differences in abscess formation
and ulcer area, there was no difference in the bacterial burden at the site of infection after
3 days suggesting that savirin is inhibiting the production of the bacterial virulence
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factors that contribute to tissue injury as opposed to affecting bacterial viability.
However, after the abscess and the ulcer begin to resolve, the bacterial burden in the
necrotic area and spleen after 7 days is decreased in the savirin treated mice indicating
that savirin enhances bacterial clearance by host innate effectors which shortens the time
of infection. Because of the timing of this effect, we suspect that macrophage-dependent
resolution of tissue injury is enhanced by savirin inhibition of several virulence factors
that impede macrophage function including capsule production and acid resistance
provided by urease and the KdpABC potassium transport operon.
Although we have yet to determine a specific mechanism of action of savirin,
there are possible mechanisms that can be eliminated. We know that the actions of savirin
are independent of the transcriptional regulator SigB because it inhibits agr signaling in
SigB–deficient strains like RN6390. Also the microarray results indicate that savirin
treatment does not lead to alterations in genes that are SigB dependent, including asp23
(Gertz et al., 1999). In addition, savirin treatment does not lead to the production of small
colony variants (data not shown) and transcripts including hemB that are induced by
compounds which lead to the development of small colony variants (Senn et al., 2005;
von Eiff et al., 1997) are not up-regulated by savirin. Because savirin induced transcripts
in both the agr+ and the ∆agr strains that promote toxic compound efflux, we addressed
whether induction of a membrane stress response would lead to either alterations in
membrane potential or in membrane integrity as demonstrated for many classical
antibiotics like daptomycin (Muthaiyan et al., 2008) and membrane disrupting agents like
hemin (Attia et al., 2010). However, savirin treatment did not alter either of these

85

properties. We speculate that savirin may be altering signal transduction leading directly
to RNAIII production. The majority of transcripts altered by savirin are directly regulated
by agr, of the 152 genes downregulated by savirin, 94 are also downregulated by deletion
of the agr operon including transcripts for the major virulence factors. Whereas other
genes not directly regulated by agr were significantly altered by savirin treatment, the
effect was more modest and their impact on the phenotype of the pathogen is uncertain.
Targeting virulence as compared to using bactericidal agents or vaccines that
induce opsonic antibodies that promote killing is a relatively new concept being applied
to S. aureus infections (Cegelski et al., 2008; Clatworthy et al., 2007; Rasko and
Sperandio, 2010). While our work is the first to describe a small molecule inhibitor for
targeting virulence rather than growth, this approach has been applied to experimental
vaccines for prevention of S. aureus infection. The inhibition of a single virulence factor
is protective in an in vivo infection where mice were immunized with a mutated form of
alpha hemolysin (Bubeck Wardenburg and Schneewind, 2008). Mice that were exposed
to H35L (a non-hemolytic mutant-alpha hemolysin) before being infected with a CAMRSA strain displayed decreased mortality in a lung infection model. In addition,
antibody neutralization of alpha hemolysin protects against dermonecrotic skin infection
(Kennedy et al., 2010) indicating that for some kinds of tissue injury, neutralization of
this single virulence factor can be protective. Savirin may have an advantage over
vaccination against a single virulence factor because it targets the production of
numerous agr-dependent virulence factors that may be essential for tissue injury at
different sites of infection. Moreover, some S. aureus strains produce little or no alpha
hemolysin like the CA-MRSA USA400 strains (Bubeck Wardenburg et al., 2007; Bubeck
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Wardenburg and Schneewind, 2008). Our work demonstrates that savirin inhibits agr
signaling in multiple agr types indicating potential for targeting virulence independent of
the genetic background of the strain and the virulence factors used to mediate the
infection.
Compounds that target virulence factor production rather than promoting bacterial
death could have therapeutic potential in clinical situations where critical host defense
factors are intact and reducing exposure to cidal antibiotics is desirable. For example, the
majority of skin and soft tissue infections, including those caused by CA-MRSA, occur in
immunocompetent individuals. In these individuals, surgical drainage alone without
additional administration of antibiotics is sufficient for clearance of the infection
(Stryjewski and Chambers, 2008). Therefore, topical administration of a compound like
savirin could be used as an adjunct to limit tissue injury and assist in promoting host
dependent clearance of the bacteria and resolution of the infection. Ideally, savirin use
would speed resolution of the infection and limit the exposure of both the patient and
bacteria to antibiotics. In addition, savirin administration could be particularly effective
in treating CA-MRSA skin infections in patients who have conditions that lead to
impaired defensins in the skin such as dermatitis. This would prevent the induction of
antibiotic resistance in this pathogen and the transmission of resistant bacteria between
hosts and throughout the environment (Deleo et al., 2010; Stryjewski and Chambers,
2008). Moreover, it would diminish the effect of antibiotic administration on normal
microbiota that help to maintain normal host mucosal barriers for the prevention of
invasive S. aureus infection. In contrast, infections in immunocompromised hosts with
impaired host defense especially those that invade beyond the blood stream will always
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require treatment with bactericidal agents. It is intriguing to speculate that compounds
like savirin could complement traditional bactericidal therapy by limiting direct tissue
injury caused by secreted virulence factors. However, further work is required to
determine if savirin would have efficacy in experimental models of these clinical settings.
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CHAPTER 4
RE-PURPOSING A GOUT DRUG, BENZBROMARONE, TO
TARGET STAPHYLOCOCCUS AUREUS VIRULENCE AND
GOLDEN PIGMENT PRODUCTION
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Introduction
The rise of community-acquired methicillin-resistant Staphylococcus aureus (CAMRSA) infections, particularly those caused by a single clone (PFGE type USA300),
coupled with the slowing of antibiotic discovery makes research into novel therapies a
priority (Lowy, 2007). One strategy emerging is to develop drugs that target bacterial
virulence factors as these are largely responsible for tissue injury and resultant morbidity
and often work by inhibiting host immune defense (Cegelski et al., 2008). The inhibition
of virulence factors would attenuate the infection and thus allow the bacteria to be cleared
by the innate immune factors of the host. Moreover, re-purposing existing drugs to target
bacterial virulence would additionally speed the pace of drug discovery as safety in
human hosts has been established. The virulence factors identified to date as essential for
CA-MRSA infection are globally regulated in part by the agr quorum sensing operon
(Novick and Geisinger, 2008; Yarwood and Schlievert, 2003). Our work identifying
apolipoprotein B as an innate barrier that antagonizes agr signaling demonstrates that
host defense against CA-MRSA infection could be accomplished by blocking agr
signaling (Peterson et al., 2008). We hypothesized that screening libraries of existing
drugs for inhibition of agr signaling could identify compounds capable of re-purposing
for targeting S. aureus virulence.
Our work in this chapter focuses on the use of a small molecule inhibitor,
benzbromarone, identified in a screen of the Prestwick library of off-patent drugs for
antagonism of agr. Benzbromarone, a drug formerly used to treat gout, inhibits both agrmediated virulence factor regulation in vitro and ameliorates a murine model of
dermonecrotic infection in vivo.

Bacteria exposed to benzbromarone were more
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susceptible to killing by several, but not all, innate immune host factors. In addition,
benzbromarone inhibits bacterial viability over a 20 hr growth curve and also inhibits
staphyloxanthin pigment production and autolysis, two agr-independent processes. These
data indicate that while benzbromarone does inhibit agr-dependent virulence, it also has
more global effects on the bacteria than originally hypothesized.

Results
Benzbromarone inhibits agr signaling and subsequent virulence factor production
Benzbromarone (Figure 1A) was one of ten compounds with an IC50<1µM
identified in a high throughput screening assay that examined compounds for possible
antagonism of agr performed by the Molecular Libraries Screening Centers Network
(MLSCN) (University of New Mexico) as well as in a screen of the Prestwick library of
off patent drugs. We used a reporter strain where activation of the agr::P3 promoter
drives expression of GFP as a preliminary test to determine whether the small molecule
benzbromarone could inhibit S. aureus agr signaling. As shown in Figure 1B,
benzbromarone inhibited AIP-dependent agr signaling in a 2 hr assay while the vehicle
alone used to solubilize the drug had no effect. We measured the viability of the bacteria
incubated with benzbromarone during both exponential and stationary phase growth. We
cultured the CA-MRSA strain LAC USA300 in TSB in the presence or absence of
benzbromarone (5 µg/ml and 10 µg/ml) and viability was evaluated by enumerating
viable colony forming units (CFU). As seen in Figure 1C, over the course of 20 hr,
benzbromarone did not affect exponential growth but significantly inhibited stationary
phase growth.
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Figure 1. Benzbromarone antagonizes agr signaling and inhibits stationary phase
growth but not exponential growth
(A) Chemical Structure of benzbromarone (CID# 2333) 1 of 10 compounds identified
with an IC50<1µM in a MLSCN screen of over 24,000 compounds
(B) Newman (2 x 107) was incubated with 50nM synthetic AIP1 in the presence or
absence of benzbromarone (5 µg/ml). After washing, fixing, and sonicating, the bacteria
were evaluated for GFP expression by flow cytometry. Data are represented as the mean
channel fluorescence (MCF) and as the mean ± SEM; ***p<0.0001, n=3
(C) LAC USA300 (2 x 107/ml TSB) was incubated in the presence or absence of
benzbromarone (5 µg/ml or 10 µg/ml) or vehicle control. Growth was determined by
plating out dilutions of the cultures on sheep blood agar and enumerating colony forming
units. Data are represented as mean ± SEM; n=3
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In addition, benzbromarone inhibited stationary phase growth of an ∆agr mutant of LAC
indicating that its effect on stationary phase metabolism was independent of agr
signaling.
Based on the results of the fluorescent-based reporter assay performed with the
lab strain Newman, we asked whether benzbromarone had a similar inhibitory effect on
quorum sensing in a more clinically relevant CA-MRSA strain. To address this, we used
qRT-PCR to measure RNAIII expression in the agr1 strain, USA300 LAC. The assay
was performed both by adding exogenous synthetically derived AIP and by allowing the
bacteria to create its own AIP endogenously. Early exponential phase USA300 LAC were
grown for 2 hr (with exogenous AIP1) or 5 hr (endogenous production of AIP1) at 37oC
in the presence of absence of benzbromarone or vehicle control added at an equal volume
as the drug. As shown in Figure 2A, RNAIII expression was significantly inhibited by the
addition of benzbromarone while no inhibition was seen with the vehicle control. Figure
2B shows a similar effect in the 5 hr assay where the AIP production was endogenous.

We then assessed the ability of benzbromarone to inhibit virulence factors
dependent on AIP-induced quorum sensing. We postulated that since the drug was able to
inhibit RNAIII production, benzbromarone would be able to inhibit the production of
virulence factors dependent on RNAIII. We first used qRT-PCR to evaluate the ability of
benzbromarone to inhibit expression of psmα, a gene target of activated AgrA (Queck et
al., 2008). As hypothesized, benzbromarone was able to inhibit psmα gene expression in
a 2 hr assay with the addition of exogenous AIP (Figure 2C). A similar procedure was
used to measure gene expression of PVL, Panton-Valentine Leukocidin, which lies
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downstream of RNAIII, in response to benzbromarone treatment. As expected, gene
expression of PVL was also significantly inhibited due to drug treatment as compared to
treatment with the vehicle control (Figure 2D). Next, we measured the ability of
benzbromarone to inhibit the production of the alpha-hemolysin toxin produced by the
USA300 strain LAC. CA-MRSA USA300 strains make substantial amounts of alphahemolysin and it is a major virulence factors for these strains (Deleo et al., 2010).
Benzbromarone inhibited the production of alpha-hemolysin to an undetectable level
(Figure 2E). These data suggest that benzbromarone is able to inhibit RNAIII activation
and the subsequent production of the downstream virulence factors of the S. aureus LAC
strain in vitro.
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Figure 2. Benzbromarone inhibits agr-dependent virulence factor production
A.C.D) LAC USA300 (2 x 107/ml TSB) was incubated with 50 nM synthetic AIP1 in the
presence or absence of benzbromarone (5 µg/ml). RNA was extracted, purified, reverse
transcribed to cDNA, and then gene expression relative to endogenous control 16s was
determined using a probe for either RNAIII after 1 hr of culture (A) n=3, PSM alpha after
2 hr of culture (B) n=2, or PVL after 2 hr of culture (C) n=3. *p<0.01, ***p<0.0005
(B) LAC USA300 (2 x 107/ml TSB) was incubated without synthetic AIP1 in the
presence or absence of benzbromarone (5 µg/ml). Expression of targets determined by
qRT-PCR as described above for RNAIII after 5 hr. ***p=0.0009, n=4
E) Effect of benzbromarone (5 µg/ml) added to an overnight culture of LAC in which
alpha-hemolysin in the supernatant was measured by lysis of rabbit erythrocytes
Data are represented as mean ± SEM
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Benzbromarone affects metabolism in both LAC USA300 agr+ and ∆agr
Staphyloxanthin is a carotenoid pigment that gives S. aureus its hallmark gold
color. It is a product of carotenoid biosynthesis pathway and is the end product of
multiple dehydrogenase reactions. Staphyloxanthin plays a role in the protection of the
bacteria from reactive oxygen species and a carotenoid-deficient mutant strain exhibited
decreased survival in a neutrophil killing assay in (Liu et al., 2005). Because
benzbromarone inhibited stationary phase growth and staphyloxanthin is produced in late
stationary phase, we determined the effect of benzbromarone on staphyloxanthin
production. We documented the production of staphyloxanthin over time by photographs
and quantified the amount of pigment by methanol extraction in LAC USA300 (Figure
3A) and LAC USA300 ∆agr mutant (Figure 3B). The pictures of Figure 3A-B illustrate
that as staphyloxanthin was produced, the addition of benzbromarone in the culture
inhibited the production of the pigment in both the LAC wild type and the ∆agr mutant
strain. This was confirmed by quantification of the pigment. These data indicate that
staphyloxanthin production is independent of agr activation and that benzbromarone has
broader effects on S. aureus than suppression of agr-dependent genes.
Autolysis is an integral part of the bacterial life cycle and, like staphyloxanthin
production, is also agr-independent. Autolysis has been proposed in bacteria to fulfill the
same function as programmed cell death observed in eukaryotic cells, that is to eliminate
damaged cells preventing these bacteria from becoming a burden to the population
(Bayles, 2007). Upon lysis, the dead bacteria release genomic DNA, termed eDNA
(extracellular DNA). This eDNA is an essential matrix molecule that provides
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intracellular adhesion and biofilm stability (Bayles, 2007; Rice and Bayles, 2008;
Sharma-Kuinkel et al., 2009). We examined the effect of benzbromarone on the
physiologic process of autolysis using the procedure described (Sieradzki and Tomasz,
1997). We predicted since benzbromarone had an effect on staphyloxanthin production,
that it might also affect another agr-independent process that occurs late in stationary
phase growth. Specifically, we cultured LAC or ∆agr mutant for 18 hr in the presence or
absence of benzbromarone before washing and resuspending in the autolysis buffer
(50mM glycine supplemented with Triton X-100). As shown in Figure 3C and 3D, the
addition of benzbromarone decreased the rate of autolysis over the course of a 28 hr
assay in both the LAC wild type and the ∆agr mutant. These data suggest that
benzbromarone prevents the bacterial cells from lysing and the resulting production of
eDNA. If eDNA production is limited, bacterial biofilm stability may be reduced limiting
the tolerance of this pathogen to commonly used antibiotics (Lewis, 2001).
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Figure 3. Effect of benzbromarone on staphyloxanthin production and bacterial
autolysis in LAC USA300 and LAC ∆agr mutant
A.B) LAC USA300 (A) or LAC USA300 ∆agr mutant (B) was incubated in TSB in the
presence or absence of benzbromarone (5 µg/ml) and staphyloxanthin production was
determined at the indicated time by removing aliquots of the culture, equalizing the
samples to an OD600, extracting the pigment with methanol, and determining the optical
density of the sample by spectrophotometer at a wavelength of 460nm.
C.D) LAC USA300 (C) or LAC USA300 ∆agr mutant (D) were cultured for 18 hr in the
presence or absence of benzbromarone (5 µg/ml). Bacteria were then chilled, washed,
and equalized to OD620 of 1.0 in 50mM glycine/0.01% Triton X-100. Cultures were
incubated at 37oC, aliquots were removed at certain timepoints, and autolysis was
measured as a decrease in OD620.
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Benzbromarone ameliorates an agr-dependent dermonecrotic S. aureus infection
Skin and soft-tissue infections predominate as the most frequent forms of disease
caused by CA-MRSA which vary in severity from painless to life-threatening with
abscesses being the most common presentations, affecting 50% to 75% of patients with
CA-MRSA (Stryjewski and Chambers, 2008). Both PSMα and alpha hemolysin are
integral factors in causing the tissue destruction of these skin and soft tissue infections (Li
et al., 2009). Because we have shown that benzbromarone inhibits the production of these
elements in vitro, we predicted that it would inhibit these factors in vivo as well and be
protective in a dermonecrotic mouse model of infection.
To address whether benzbromarone administration would be protective in an
invasive S. aureus infection, we used a mouse model of dermonecrosis (Wang et al.,
2007). Early exponential phase bacteria were injected subcutaneously into the flank of
SKH1-E mice with the addition of either benzbromarone or vehicle alone. The infections
were monitored for two days and abscess volume, ulcer area, and weight loss recorded.
At the termination of the experiment, the ulcerated areas were excised and homogenized
to determine the number of bacteria in the area. As shown in Figure 4A and 4B, infection
of the mice with LAC in the presence of benzbromarone resulted in smaller abscesses and
ulcer size as compared to those given vehicle while the LAC ∆agr bacteria were unable
to produce a necrotic ulcer. These data show that benzbromarone is protective in a
dermonecrotic infection with LAC USA300 and suggests that benzbromarone may be
able to be utilized as a therapeutic. Next, in an effort to make the experiment more
clinically relevant, we tested whether benzbromarone administration could protect against
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dermonecrosis from other agr types in vivo. We infected mice as before using agr2 and
agr3 strains. Our results show that benzbromarone exhibited protection in an agr2 (502A
strain) (Figure 4C) and an agr3 (1560 strain) (Figure 4D) S. aureus infection. These data
indicate that benzbromarone is protective in an in vivo dermonecrotic infection and may
be a useful therapeutic against skin and soft tissue infections caused by CA-MRSA.
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Figure 4. Effect of benzbromarone on an invasive dermonecrotic S. aureus infection
of multiple agr types
A) LAC USA300 WT or LAC USA300 ∆agr mutant (2 x 107/ml saline at early
exponential phase) were injected subcutaneously on the flank (n=8 mice for each group)
with either 5 µg benzbromarone or equal volume of vehicle. Pictures of the injection sites
were taken at two days
B) Measurements of dermonecrosis (ulcer area) were taken on Day 2 of the infection.
***p=0.0005, Data represented as the mean ± SEM
C.D) 502A (C) or 1560 (D) (2 x 107/ml saline at early exponential phase) were injected
subcutaneously on the flank (n=4 mice for each group) with either 5 µg benzbromarone
or equal volume of vehicle. Pictures of the injection sites were taken at two days.
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Benzbromarone treatment results in increased susceptibility of the bacteria to
killing by some, but not all, innate immune host factors
Targeting virulence using benzbromarone should attenuate the bacteria thus allowing the
host innate immune system to clear the bacteria. We postulated that to be an effective
therapeutic, benzbromarone treatment would enhance bacterial killing by the host innate
immune system, including low pH. Acidic conditions exist in niches like the skin as well
as phagolysosome of macrophages to combat pathogens. S. aureus expresses several
factors to resist these acidic environments. We used in vitro tests with acidic buffer to
replicate the host innate effector to determine if exposure to benzbromarone made the
bacteria more susceptible to killing by acid. Following treatment with benzbromarone or
vehicle, the bacteria were incubated in PBS (pH 2.5) for 2 hr. As shown in Figure 5A and
5B, both the wild type bacteria and the ∆agr strain were significantly more susceptible to
killing by acid following treatment by benzbromarone (Figure 5A). These data indicate
that benzbromarone impairs an acid resistance mechanism that is independent of agr
signaling.
Because benzbromarone inhibited pigment production and staphyloxanthin
provides defense against reactive oxygen intermediates (Liu et al., 2005), we predicted
that benzbromarone treatment would make the bacteria more susceptible to killing by
hydrogen peroxide. LAC USA300 was incubated for 30 hr in the presence or absence of
benzbromarone and then subjected to hydrogen peroxide at final concentrations of 1.5%
and 3.0% for 2 hr. As shown in Figure 5C, the wild type bacteria that had been cultured
in the presence of benzbromarone had significantly more killing than bacteria alone at
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two different percentages of hydrogen peroxide as compared to the control indicating that
benzbromarone does confer increased susceptibility to at least one oxidant.
Linoleic acid is a free fatty acid that is bacterial lytic lipid constituent of the skin
and provides host defense at mucosal barriers (Kenny et al., 2009). LAC USA300 was
incubated for 18 hr in the presence or absence of benzbromarone after which were
challenged with increasing concentrations of linoleic acid and incubated an additional 18
hr. Shown in Figure 5D, benzbromarone treatment had no effect on the survival of the
bacteria when incubated with linoleic acid. These data suggest that exposure to
benzbromarone makes the bacteria more susceptible to killing by some but not all
immune effectors we tested.
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Figure 5. Treatment of LAC USA300 with benzbromarone results in increased
killing by some, but not all, tested host immune factors
A.B) LAC USA300 or LAC USA300 ∆agr mutant (1 x 109/ml TSB) were incubated for
1.5hr in the presence or absence of benzbromarone (5 µg/ml). Bacteria were centrifuged
and resuspended in PBS, pH 2.5 for 2hr. Dilutions were plated on sheep blood agar and
viability determined by enumerating colony forming units. *p<0.1, n=6, Data represented
as the mean ± SEM.
C) Early exponential phase LAC USA300 was incubated in TSB for 30 hr in the presence
or absence of benzbromarone (5 µg/ml). Bacteria were centrifuged, washed twice, and
resuspended in PBS to an OD600 of 0.6. H2O2 was added to a final concentration of 1.5%
or 3% and incubated for 2 hr. Catalase was added (1000 U/ml) to quench the reaction.
Dilutions were plated on sheep blood agar and viability determined by enumerating
colony forming units. *p<0.1, n=6.
D) Early exponential phase LAC USA300 were incubated in TSB for 18 hr in the
presence or absence of benzbromarone (5 µg/ml). Bacteria were centrifuged, washed
twice, and resuspended in TSB to an OD600 of 0.3. Linoleic acid was added to 1ml
volumes of the cultures to final concentrations ranging from 0.2 mM to 1.0mM. Bacteria
with linoleic acid were incubated an additional 18 hr then sonicated and dilutions were
plated on blood agar and surviving bacteria were determined by enumerating colony
forming units. n=3.
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Discussion
CA-MRSA is resistant to most commonly used antibiotics and also has
mechanisms to escape host immune capture and killing (Graves et al., 2010). The
emergence of hypervirulent, antibiotic-resistant strains emphasizes the need to develop
effective therapeutics to which the bacteria will develop limited resistance to. One
strategy illustrated here and by others is the targeting of bacterial virulence factors which
contribute to disease.(Alksne and Dunman, 2008; Garcia-Lara et al., 2005a). Host
defense mechanisms inhibit quorum sensing dependent virulence factor production such
as hemoglobin (Schlievert et al., 2007), neutrophils (Rothfork et al., 2004), and
apolipoprotein B (Peterson et al., 2008) and therefore providing a therapeutic that targets
virulence regulation during some types of S. aureus infections is one mechanism for restoring host defense. Here we have shown results which indicate that bacterial virulence
production can be inhibited by the small molecule, benzbromarone. Moreover, because
benzbromarone is an off patent drug formerly used for the treatment of gout, re-purposing
it to target S. aureus virulence is yet another mechanism for speeding drug discovery.
The data presented here show the ability of a compound, benzbromarone, to target
the production of agr-dependent virulence factors. Our results show that it is capable of
inhibiting RNAIII production and subsequent downstream virulence factor production
seen at both the transcript and protein level. We confirm in our in vivo dermonecrosis
model of infection that agr-dependent quorum sensing is required for the formation of
dermonecrotic ulcer, an observation made by others (Wang et al., 2007) and we also
illustrate that benzbromarone is protective in an infection with the CA-MRSA strain LAC
USA300. This in vivo protection also extends to other agr backgrounds. While
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administration at the time of infection demonstrates efficacy, whether it can be given later
during the course of the infection is yet to be determined. Our data indicate that ongoing
quorum sensing is required to achieve maximal necrosis and therefore we would predict
that administration of benzbromarone after the initiation of the infection should be
efficacious.
In addition to its effect on agr signaling, benzbromarone inhibited stationary
phase growth but not exponential phase growth of both agr+ and ∆agr strains indicating
that it has more broad effects on metabolism. However, this pattern of growth inhibition
is unique and true antibiotics that target metabolic pathways like protein synthesis, cell
wall production, or nucleotide synthesis inhibit exponential phase growth. While
unexpected, stationary phase growth inhibition could have a therapeutic benefit for
biofilm infections or stages of infection where stationary phase growth is achieved.
Consistent with this late stage effect on metabolism, benzbromrone also inhibits
production of staphyloxanthin, a carotenoid pigment used by the bacteria as protection
against oxidants that is optimally produced during late stationary phase. Because
cholesterol lowering drugs that inhibit staphyloxanthin production have therapeutic
benefit against experimental S. aureus infection (Liu et al., 2008), one mechanism by
which benzbromarone could provide a therapeutic benefit in vivo is through
staphyloxanthin inhibition.
The mechanism of action of benzbromarone alters signaling and metabolic
pathways in the bacteria that make them more susceptible to killing by some but not all
host immune effectors. Because an increased susceptibility to acid killing was observed
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at a time prior to growth or staphyloxanthin inhibition, and for both agr+ and ∆agr
strains, we suspect that this involves overcoming both agr-dependent and agrindependent gene regulation. Gene products that are suspected to provide defense against
acid include urease-mediated production of ammonia, the function of the osmotic sensor
and potassium transporter KdpABC, and arginine deiminase production of ammonia.
Microarray analysis comparing LAC USA300 wild type to its agr deletion mutant
demonstrated that both the urease and KdpABC operons are agr regulated while arginine
deiminase is not. Thus, the use of benzbromarone as an adjunct for treating skin infection
could assist in acid killing at mucosal barriers and within phagolysosomes. In addition to
increased susceptibility to acid killing, benzbromarone also increased susceptibility to
hydrogen peroxide killing. Because this increased susceptibility occurred only at a time
by which staphyloxanthin is inhibited, we suspect that this increased killing is mediated
by a failure of the bacteria to scavenge the reactive oxidants permitting their action on
critical pathways like DNA synthesis.
Due to its more global effects on processes such as stationary phase growth,
staphyloxanthin production, and autolysis, benzbromarone is not sufficiently selective for
agr-dependent virulence factors to function exclusively as an anti-virulence compound.
The inhibitory actions of benzbromarone on growth and metabolic pathways suggest that
bacterial resistance to its effects could be developed. However, even with this limitation,
the mechanism by which it selectively inhibits stationary phase growth could have
therapeutic benefits in particular infections where that pattern of growth predominates,
such as in biofilm infections.
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CHAPTER 5
DISCUSSION AND CONCLUSIONS
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Summary and Future Directions
Mammalian hosts have evolved numerous mechanisms that target and inhibit S.
aureus quorum sensing-dependent virulence. Upon infection, neutrophils are recruited to
the site where the reactive oxygen species they create inactivate the peptide pheromones
that drive agr signaling (Rothfork et al., 2004), host hemoglobin inhibits the secretion of
the peptide pheromone through AgrB (Attia et al., 2010; Schlievert et al., 2007), and
apolipoprotein B of LDL and VLDL particles binds to and sequesters the pheromone,
inhibiting the signaling of AgrC. The ability of the chemical compounds described here
to antagonize quorum sensing could act as additional inhibitors to pheromone signaling
and virulence factor production that could attenuate the infection and thus facilitate
clearance by the immune system of the host.
The work presented here describes a role for small molecular compounds as
inhibitors of S. aureus virulence. Although anti-virulence compounds have been
developed for Gram-negative infections (Cegelski et al., 2008; Clatworthy et al., 2007;
Rasko and Sperandio, 2010), this is the first description of small molecule inhibitors
utilized in a Gram-positive organism to target quorum sensing-dependent virulence both
in vitro and in vivo. The compound savirin met all of the necessary criteria we established
to be a potential relevant therapeutic for the treatment of CA-MRSA infections. Savirin
inhibits bacterial virulence without affecting viability, works in multiple agr
backgrounds, does not induce resistance to savirin during the time frame we utilized, and
enhances the susceptibility of the bacteria to killing by low pH. In contrast,
benzbromarone, which has the advantage of already being an FDA approved drug,
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appears to have a much more global effect on S. aureus, affecting not only RNAIII
expression and downstream virulence factors, but also staphyloxanthin production,
autolysis, and stationary phase growth. While these actions of benzbromarone on
metabolism components of S. aureus may create a selective pressure and lead to the loss
of sensitivity of the bacteria to the drug, these additional effects could also be
advantageous. For example, conventional antibiotics target exponential growth. The
ability of benzbromarone to inhibit stationary phase growth could have utility during
infections where the bacteria have reached stationary phase and are relatively resistant to
killing by conventional antibiotics.
Other known antagonists of S. aureus virulence include competing AIPs (Lyon et
al., 2002; Wright et al., 2005) and Lactobacillus reuteri-produced cyclic dipeptides (Li et
al., 2011). Type 2 AIPs exhibited inhibition of quorum sensing in an agr1 infection by
binding to the AgrC receptor, blocking the binding of the type 1 AIPs being released by
the bacteria. This binding of AIP2 blocked signaling through AgrC and inhibited the
expression of RNAIII and the production of virulence factors. In addition, administration
of AIP2 prior to an agr1 experimental skin infection conferred protection in an animal
model (Wright et al., 2005). The cyclic dipeptides produced from Lactobacillus reuteri
inhibit agr dependent-quorum sensing and toxin production in vitro but whether this
would provide protection in vivo has not been addressed (Li et al., 2011). Intriguingly,
these peptides also inhibit signaling through other sensor-regulators used by S. aureus to
regulate gene expression in addition to agr. Thus, these could have more broad effects on
global gene regulation and could represent a mechanism by which normal microbiota
provide defense against invasive S. aureus infection. Another mechanism for targeting
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virulence is vaccination with modified virulence factors that induce neutralizing
antibodies but are not themselves capable of significant tissue injury. The inhibition of a
single virulence factor provided protection in an in vivo infection where mice were
immunized with a mutated form of alpha hemolysin (Bubeck Wardenburg and
Schneewind, 2008). Mice that were vaccinated with a variant of alpha hemolysin at a
single amino acid site (H35L) before being infected with a CA-MRSA strain had
significantly decreased mortality in a lung infection model. Moreover, antibody
neutralization of alpha hemolysin was sufficient to protect mice from an experimental
dermonecrotic skin infection (Kennedy et al., 2010). In comparison to these approaches,
the use of a compound like savirin has several advantages. First, as a non-peptide
antagonist it would have greater stability in blood and tissues where proteases can
actively cleave peptides. Secondly, it targets the production of numerous agr-dependent
virulence factors as opposed to only one and there are numerous clinical isolates that
produce minimal or no alpha hemolysin but still rely on agr signaling to regulate
virulence.
The microarray analysis of stationary phase, savirin-treated S. aureus
demonstrated the extent of the specificity of the savirin to agr signaling. The analysis of
the actual genes altered revealed that 94 open reading frames significantly downregulated by savirin in the agr+ strain were also down regulated in the absence of agr,
including all of the major virulence factors regulated by agr. This shows great selectivity
of the small molecule to the targeting of agr-dependent genes. To look at the effect of
savirin from a more global view, we looked at the savirin-altered genes in relation to the
entire S. aureus genome. The USA300 genome has a total of 2770 open reading frames
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and savirin affects 211 of them. These data show that the effect of savirin is relatively
minor, leaving almost 93% of the open reading frames of the bacteria unaffected. When
S. aureus strain ATCC 29213 was exposed to daptomycin, the antibiotic effected the
transcription of 869 open reading frames, over four times the number of open reading
frames affected by savirin (Muthaiyan et al., 2008). This study, as well as others,
demonstrate that conventional antibiotics used at sub-inhibitory concentrations alter gene
transcription in a much more global fashion.
Several aspects of the action of both small molecules described here remain to be
elucidated, most importantly being a precise mechanism of action. From the microarray
analysis, we postulate that savirin passes through the bacterial membrane becoming
intracellular due to the creation of a membrane stress response, seen as an up-regulation
of efflux pumps and transporter genes. This stress response is characteristic of the actions
of traditional antibiotics which alter either the membrane potential or membrane integrity.
However, the stress response induced by savirin was not sufficient to alter either one of
these membrane events. We believe the up-regulation is in response to the bacteria
sensing something foreign or toxic and attempting to transport savirin out of the cell. This
may be due to the quinolone structure that comprises a portion of the savirin molecule.
Fluoroquinolones, a family of broad-spectrum antibiotics, are the antibiotics most
associated with the up-regulation of these efflux pumps. These drugs act by interfering
with DNA replication and transcription and they share a quinolone ring system
(Kleinkauf et al., 2001), which is also seen in savirin. Thus, we postulate that the
quinolone ring structure of savirin is responsible for the up-regulation of the efflux pump
but in the absence of a required halide, it is not sufficient for targeting DNA replication.
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Similar to the results of our microarrarray analysis, others have shown similar upregulation of membrane transport genes upon antibiotic exposure. For example, upon
treatment with berberine chloride, a protoberberine alkaloid with antimicrobial activity, a
large number (98) of putative transporter genes were differentially regulated and
transcripts for several multidrug resistance transporters were up-regulated 10-20 fold
(Wang et al., 2008). In contrast, while savirin up-regulated transcripts involved in
membrane transport, the fold increase and the number of genes up-regulated were modest
compared to the actions of conventional antimicrobials. Due to the selectivity of the
effects of savirin on agr-dependent genes, we postulate that savirin is having a direct
interaction with agr, possibly by binding to a RNA polymerase directly preceding the P3
promoter.
Another aspect of savirin treatment that requires more investigation is the effect
the molecule has on biofilm formation. From the microarray analysis, the up-regulation
of adhesive factors such as SpA leads us to predict that savirin treatment may result in a
phenotypic shift towards biofilm formation. However, a potassium-specific transport
system that is up-regulated in biofilms is inhibited upon exposure to savirin. Three genes
of the kdp operon, kdpABC are induced in biofilms as compared to planktonic growth
conditions (Beenken et al., 2004). The kdp operon contributes to pH homeostasis through
exchange of K+ to H+ which is accomplished by kdpD, a membrane spanning sensor
kinase that responds to osmotic pressure, membrane stretch, or potassium level, and thus
transphosphorylating KdpE, a cytosolic transcriptional activator, which then up-regulates
transcription of the kdpFABC operon. Our microarray analysis shows that kdpDE is also
down-regulated in response to savirin while others have shown the two genes to be up-
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regulated in biofilms compared to the exponential growth phase (Beenken et al., 2004).
Two other significant biofilm-related genes affected by savirin encode surfactant like
proteins and proteases. Production of these components is essential for the release of
clumps of biofilm and dispersal of the bacteria (Boles and Horswill, 2008; Wang et al.,
2011). If savirin exposure did lead to biofilm production, the dispersal of clumps of the
biofilm would most likely be inhibited. An animal model that could be useful to
determine the effect of savirin on biofilm formation is an air pouch model of S. aureus
infection (Peterson et al., 2008). The epithelial lining of the pouch could be excised and
treated with an anti-staphylococcal antibody so bacteria and biofilm production could be
visualized and quantified using confocal microscopy. In this manner, whether savirin
administration enhances biofilm growth on the damaged tissue could be determined.
Another result from the microarray analysis that should be examined is the
contribution that the alteration of TCA genes contributes to the mechanism of action of
savirin. Citrate synthase and acetyl coenzyme A are two genes of the TCA cycle that are
down-regulated by savirin. This suppression may cause concern since affecting bacterial
metabolism may lead to the development of resistance however the effect is a relatively
modest 2-3-fold inhibition. The TCA cycle is one of three metabolic pathways of S.
aureus and is largely repressed in nutrient abundant media (Somerville and Proctor,
2009). This could explain why we do not see inhibited growth in our in vitro assays that
are performed in trypticase soy broth. It is unclear thus far whether these effects on the
TCA cycle are linked to agr signaling or if they are a separate effect. If the alterations of
the TCA cycle are a not an essential component of the mechanism for inhibition of agr
signaling, then even if the bacteria develop resistance to the inhibitory actions on the
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metabolic pathways, the bacteria will still remain sensitive to the anti-virulence effects of
savirin and the infection will still be attenuated upon administration of the small
molecule.
Therapeutic application of savirin is an area with many avenues for investigation
as well. An obvious question is whether the anti-virulence actions of savirin are specific
to S. aureus or if savirin could be a useful therapeutic for other Gram-positive infections.
A related pathogen we would investigate first would be S. epidermis. Since savirin
appears to act on agr signaling, we would predict that savirin would have an equally
inhibitory effect on S. epidermis given that this bacteria also has an agr operon (Otto,
2009). Clinically, it would be of interest whether savirin would work in concert with
traditional antibiotics. We could utilize our in vivo model of dermonecrosis to see if
infections treated with antibiotics in addition to savirin would create smaller ulcers
initially, due to the inhibition of virulence by savirin, and then exhibit decreased time to
resolution and bacterial clearance due to the actions of the antibiotic. Whether or not
there would be an additive effect between the two treatments is unknown. The action of
savirin on systemic S. aureus infections has also yet to be investigated. The air pouch
model of S. aureus infection could be utilized again to determine the extent of bacterial
invasion. The pouch tissue and underlying muscle could be excised and stained with antistaphylococcal antibody to determine if savirin treatment kept the bacteria from invading
through the tissues into the dermis or muscle as described (Peterson et al., 2008). Other
clinically relevant questions include whether savirin could be effective after the infection
has been established as well as if savirin treatment could be administered as a
prophylactic for incoming hospital patients to prevent acquisition of a CA-MRSA
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infection. We can use our in vivo dermonecrosis model to determine if these treatments
are protective and feasible before they can be proposed for clinically useful therapeutics
in humans.
The current therapy for skin and soft tissue infections is surgical drainage,
required by ~80% of the patients that present to an emergency department with purulent
infections (Stryjewski and Chambers, 2008). These patients are frequently cured by
surgical drainage alone and are postulated to not require antibacterial therapy. In fact a
clinical trial reported cure rates of >85% for patients who underwent surgical drainage
and received a placebo and the response was equivalent to patients who underwent
surgical drainage and were given cephalexin (Stryjewski and Chambers, 2008). These
results indicate that there are clinical scenarios where antibiotics are not absolutely
required. In cases where surgical drainage alone may be appropriate (the patient is
healthy and the lesion is small) the small molecule inhibitors described here, savirin and
benzbromarone, could be used as adjunct drug therapies to speed the resolution of the
infection. Administration of savirin may be useful in the treatment of CA-MRSA
infections in patients with dermatitis or other similar skin conditions. The inhibition of
virulence factor production by the bacteria may limit the amount of tissue damage in
these people who have impaired skin defensins as well as limit the exposure of the patient
and bacteria to antibiotics, thus preventing their negative consequences.

Conclusions
The results presented here describe the ability of two small molecular compounds to
target quorum sensing-dependent virulence production of S. aureus. While this approach
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of targeting virulence has shown promise in Gram negative in vivo infections (Cegelski et
al., 2008; Clatworthy et al., 2007; Rasko and Sperandio, 2010), it has yet to be applied to
Gram-positive pathogens. This work demonstrates that benzbromarone and savirin, two
molecules identified in a high throughput screening assay examining compounds for
possible antagonism of agr, are able to inhibit S. aureus virulence in vitro and in vivo.
One molecule addressed here, savirin, has the ability to inhibit bacterial virulence without
affecting viability, has the ability to inhibit virulence in multiple agr backgrounds,
remains effective over the timecourse tested without induction of bacterial resistance, and
also makes the bacteria more susceptible to killing by acidic conditions, a host immune
effector. The demonstration of the protective effects of savirin and benzbromarone in an
in vivo dermonecrotic infection shows the potential of these compounds as a clinically
relevant therapeutic for immunocompetent patients. Savirin- and benzbromarone-treated
bacteria create smaller areas of dermonecrosis in addition to a faster ulcer resolution and
bacterial clearance over time.
With the emergence of the hypervirulent CA-MRSA strains which produce
abundant amounts of tissue-destroying virulence factors and an ability to develop
resistance to most antibiotics, identifying novel therapeutics has renewed importance.
The results presented here show that both savirin and benzbromarone are effective
inhibitors of CA-MRSA virulence factor production and confers protection in an animal
model of CA-MRSA infection.
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